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THE ROLE OF BCL-2 FAMILY IN CLINICAL RESPONSE OF
CHRONIC LYMPHOCYTIC LEUKEMIA

SAYER ALHARBI

ABSTRACT
The anti-apoptotic Bcl-2 proteins regulate lymphocyte survival and are overexpressed in lymphoid malignancies, including chronic lymphocytic leukemia
(CLL). The small molecule inhibitor ABT-737 binds with high affinity to Bcl-2,
Bcl-xl, and Bcl-w but with low affinity to Mcl-1, Bfl-1, and Bcl-b. The active
analog of ABT-737, navitoclax, has shown a high therapeutic index in lymphoid
malignancies; developing a predictive marker for it would be clinically valuable
for patient selection or choice of drug combinations. We compared expression of
anti-apoptotic Bcl-2 genes that are known to be targeted by ABT-737. Our
findings reveal that the relative ratio of Mcl-1 and Bfl-1 to Bcl-2 expression
provides a highly significant linear correlation with ABT-737 sensitivity (r = 0.6,
P < .001). The (Mcl-1 + Bfl-1)/Bcl-2 ratio was validated in a panel of leukemic
cell lines subjected to genetic and pharmacologic manipulations. We also tested
whether anti-apoptotic Bcl-2 proteins can be used as prognostic marker in CLL,
since the current prognostic markers, such as CD38 and ZAP70 fail to predict the
clinical outcome in a substantial number of CLL patients. Our findings indicate
that only high Bcl-xl expression is strongly correlated (P=0.002) with short
IV

treatment-free survival. Strikingly, Bcl-xl was able to identify patients with high
risk in the ZAP70 negative and CD38 negative groups as well as in patients with
normal/unknown p53 deletion, thus providing a very powerful prognostic value
for CLL. Finally, we investigated the potential mechanism responsible for ABT737 resistance in leukemic cell lines. Compared with parental cells, cells that have
developed acquired resistance to ABT-737 showed increased expression of Mcl-1
due to increased protein stability. Interestingly, increased Mcl-1 levels sequester
the BH3-only protein Bim which mediates resistance to ABT-737. These data
therefore reveal novel insights into the role of anti-apoptotic Bcl-2 proteins in
clinical response, acquired resistance, and tumor progression in CLL patients.
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CHAPTER I
INTRODUCTION

1.1 Apoptosis
Apoptosis, or programmed cell death, is a cellular mechanism used to eliminate
cells that are injured, infected, or have reached the end of their life span (Kerr,
Wyllie et al. 1972). This process is tightly regulated by a family of proteases called
caspases, which are normally found in healthy cells as inactive precursors, but which
become activated during apoptosis (Autret and Martin 2009). Apoptosis ensures
removal of cellular bodies before these cells can rupture and release their contents.
This process is critical, as cell rupture caused by necrosis can provoke inflammatory
immune reactions that can augment promote damage and lead to further cell death
(Chen, Kono et al. 2007). Disturbed regulation of apoptosis can lead to many
diseases, including cancer, autoimmunity, and degenerative disorders (Cory and
Adams 2002). Apoptotic cell death is characterized by a series of morphological and
biochemical features, such as plasma membrane blebbing, chromatin condensation,
DNA cleavage, and exposure of phosphatidylserine on the extracellular side of the
plasma membrane (Bouillet and Strasser 2002).
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1.2 Apoptosis pathways
There are two predominant pathways that cells utilize to trigger apoptosis. The
two pathways of apoptosis can be distinguished by whether the Bcl-2 family
proteins are involved and which caspases are critical for mediating the cell death
(Youle and Strasser 2008). The intrinsic pathway or mitochondrial pathway is
mediated by the Bcl-2 family and primarily leads to the activation of caspase-9
(Hakem, Hakem et al. 1998). The Bcl-2 family consists of anti and pro-apoptotic
members that mediate opposing functions to control life or cell death in the
intrinsic pathway by controlling the integrity of the outer mitochondrial
membrane (OMM).
Bcl-2 family members are classified into anti-apoptotic and pro-apoptotic
(Chipuk, Moldoveanu et al. 2010). Anti-apoptotic members include Bcl-2-related
gene (Bcl-2), Bcl-2-related gene A1 (A1), long isoform (Bcl-xl), Bcl-2-like 2
(Bcl-w), Bcl-b and myeloid cell leukemia 1 (Mcl-1). The anti-apoptotic members
work predominantly to inhibit apoptosis by sequestering pro-apoptotic proteins
and blocking their ability to oligomerize and advance the outer mitochondrial
membrane permeabilization (OMMP).

The pro-apoptotic Bcl-2 members are

divided into the effector proteins and the BH3-only proteins. The effector proteins
Bcl-2 antagonist killer 1 (Bak) and Bcl-2-associated x protein (Bax) can initiate
apoptosis by causing pores within the OMM to promote MOMP. The BH3-only
proteins Bad, Bid, Bim, Noxa, and Puma have a conserved BH3 domain that can
bind to the anti-apoptotic Bcl-2 proteins and thus allow the effector proteins to be
released and then promote apoptosis.
2

The intrinsic pathway can be triggered by various intracellular stresses,
including cytokine deprivation and genotoxic damage (Zha, Harada et al. 1996;
Oda, Ohki et al. 2000) (Figure 1.1). Once the intrinsic pathway is triggered, this
promotes MOMP, which allows cytochrome c, located in the mitochondrial
intermembrane space (IMS), to be released into the cytosol. Cytochrome c
engages apoptotic protease activating factor-1 (APAF-1) to oligomerize into a
caspase activation complex called the apoptosome. This binds and promotes the
activation of initiator caspase-9, which then activates executioner caspases-3 and 7 (Li, Nijhawan et al. 1997).

3

Figure 1.1: Scheme showing intrinsic and extrinsic pathways of apoptosis.
Apoptosis can be induced by intrinsic or extrinsic pathways. The intrinsic
pathway is activated either by BH3-only protein induction or by post-translational
modification which resulted in inhibition of the anti-apoptotic Bcl-2 proteins. This
releases BAK or BAX, which in turn release cytochrome c and promote apoptosis
by activating APAF1 and caspases. The extrinsic pathway can be activated
directly by caspase-8, which leads to caspase-3 activation and cell death. The
intrinsic pathway can be linked to the extrinsic pathway through cleaved BID.
Modified from (Youle and Strasser 2008).
4

The extrinsic pathway is activated by ligation of death receptors at the cell
surface independently of the Bcl-2 family. The tumor necrosis factor (TNF)
receptor family members, such as Fas or TNF receptor-1 (TNFR1), contain an
intracellular death domain that can recruit and activate caspase-8 through the
adaptor protein Fas-associated death domain (FADD). This recruitment leads to
activation of downstream caspases, such as caspase-3, -6, or -7 (Ashkenazi 2002;
Almasan and Ashkenazi 2003). Interestingly, the extrinsic pathway can be linked
with the intrinsic pathway through caspase-8 cleavage-mediated activation of the
pro-apoptotic BH3-only protein Bid (Li, Zhu et al. 1998; Luo, Budihardjo et al.
1998). The cleaved Bid (tBid) can translocate to the mitochondria and further
activate caspase through the intrinsic pathway (Figure 1.1).

1.3 Bcl-2 family structure
The Bcl-2 family shares at least one conserved homology domain, called the
Bcl-2 homology (BH) domain (Youle and Strasser 2008) (Figure 1.2). Antiapoptotic Bcl-2 proteins contain four Bcl-2 homology domains (BH1–4) and are
mostly localized within the OMM. The carboxy terminal hydrophobic
transmembrane domain (TM) of the anti-apoptotic Bcl-2 proteins mediates its
targeting to the outer mitochondrial membrane, where the BH1-BH3 domains and
the N-terminal BH4 domain stabilizes the structure (Tzifi, Economopoulou et al.
2012). BH1-BH3 domains also form a hydrophobic groove on the surface of anti-

5

apoptotic proteins that can be targeted by the BH3 domain of their pro-apoptotic
ligands (Sattler, Liang et al. 1997).
The three-dimensional structure is conserved between Bcl-xl and Bcl-2
(Petros, Medek et al. 2001). However, there are similarities and differences
between the Bcl-2 cores of anti-apoptotic proteins and the BH3 peptide binding
(Chipuk, Moldoveanu et al. 2010), thus creating a preferential binding between
anti-apoptotic and BH3-only Bcl-2 family proteins. For example, Bim and Puma
can bind to all anti-apoptotic proteins, where Noxa binds only to Mcl-1 and Bfl-1
(Figure 1.3). These variations in the Bcl-2 cores are critical to cancer drug
discovery, as Mcl-1 and Bfl-1 are not targeted by the most promising BH3
mimetic, ABT-737, which only inhibits Bcl-2, Bcl-w, and Bcl-xl (Oltersdorf,
Elmore et al. 2005).

6

Figure 1.2: The Bcl-2 family related proteins. This family comprises antiapoptotic (highlighted in green boxes), pro-apoptotic (highlighted in blue) and
BH3-only proteins (highlighted in orange). The anti-apoptotic and pro-apoptotic
proteins share four Bcl-2 homology domains BH1-4, where BH3-only proteins
display only one BH3 domain. Modified from (Lessene, Czabotar et al. 2008).

7

.

Figure 1.3. The binding specificity of BH3-only proteins for anti-apoptotic
Bcl-2 family proteins. Bim, Bid and Puma can bind to all anti-apoptotic Bcl-2
family proteins. Noxa binds only to Mcl-1 and Bfl-1 (A1), where as Bad binds to
Bcl-1, Bcl-xl, and Bcl-w. Modified from (Youle and Strasser 2008).
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The effector proteins Bax and Bak were first described as containing only
BH1-3 domains, however it was later discovered that they also contain a BH4
domain (Kvansakul, Yang et al. 2008). The BH3-only proteins contain a BH3
domain that is essential for binding to the anti-apoptotic members and mediating
apoptosis (Huang and Strasser 2000). The BH3 peptide is an amphipathic α-helix
of around 15 amino acids long that binds to the hydrophobic groove of the antiapoptotic Bcl-2-family proteins (Zha, Aime-Sempe et al. 1996). The BH3-only
proteins are divided into direct activator (Bim and Bid) and sensitizers/derepressor (Bad, Noxa, and Puma) proteins.

1.4 Bax and Bak activation models
Initiation of apoptosis requires not only pro-apoptotic family members, such as
Bax and Bak, but also the BH3-only proteins. However, the BH3-only proteins
alone fail to induce apoptosis in the absence of Bax and Bak (Zong, Lindsten et
al. 2001). During apoptosis, Bax and Bak oligomerize into the mitochondrial
outer membrane, disrupt its integrity and release cytochrome c, which allows
activation of caspases (Wei, Zong et al. 2001). The BH3-only proteins Bid and
Bim can directly trigger Bax and Bak activation whereas the other members were
suggested to activate Bax and Bak indirectly (Wei, Lindsten et al. 2000; Letai,
Bassik et al. 2002). In fact, there are three models for activating Bax and Bak:
sensitizer, de-repressor, and neutralization models (Chipuk, Moldoveanu et al.
2010) (Figure 1.4). According to the sensitizer model, an anti-apoptotic protein
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is sequestered with a BH3-only protein and this interaction blocks the inhibition
of direct activators (Letai, Bassik et al. 2002). For example, if Bcl-2 is in complex
with Puma, any further induction of Bim will not be inhibited, since Bcl-2 is
already sequestered by Puma and in this case MOMP will proceed (Figure 1.4A).
According to the derepression model, a direct activator is inhibited by an antiapoptotic Bcl-2 protein, and any cellular stress induces a BH3-only protein,
which then releases the direct activator from Bcl-2 and promotes MOMP (Certo,
Del Gaizo Moore et al. 2006; Del Gaizo Moore, Brown et al. 2007) (Figure 1.4B).
In the neutralization model, the effecter protein Bax or Bak is inhibited (Uren,
Dewson et al. 2007). For example, activated Bak is sequestered by the antiapoptotic Bcl-2, and following any cellular stress, a BH3-only protein will be
induced to neutralize the anti-apoptotic protein, which frees Bak, and then
promotes apoptosis (Figure 1.4C).

Activation of Bax appears to involve sub-cellular translocation and
oligomerization.

In healthy cells, Bax is localized as an inactive form in the

cytosol where an α9 helix in the C-terminal occupies its BH3 binding
hydrophobic groove, which inhibits both its mitochondrial localization and proapoptotic activity (Suzuki, Youle et al. 2000). During apoptosis, Bax undergoes
conformational change, which allows to translocate to the mitochondria by
inserting its C-terminal into the OMM and thus, allowing its BH3 domain
exposure, which mediates Bax oligomerization. Unlike Bax, Bak is localized on
the mitochondria, where it is sequestered by anti-apoptotic Mcl-1 and Bcl-xl to
10

prevent its oligomerization (Willis, Chen et al. 2005). Following cytotoxic signals
that activate BH3-only proteins, the interaction can be disrupted by the BH3-only
proteins where Bak can be released from the anti-apoptotic proteins and promote
apoptosis.
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Figure 1.4: Three models for activating Bax and Bak by BH3-only proteins.
(A) Sensitizer model: BH3-only protein inhibits the anti-apoptotic Bcl-2 protein.
Upon activation following a cellular stress, a direct activator can not be inhibited
and will go directly to promote MOMP. (B) De-repressor model. A direct
activator (BIM) is sequestered by an anti-apoptotic Bcl-2 protein. Following
cellular stress, a de-repressor BH3-only protein is induced and releases the direct
activator from the anti-apoptotic protein and then MOMP proceeds. (C) The
neutralization model: The effector BAK is inhibited by the anti-apoptotic protein.
Following cellular stress, BH3-only protein is induced and then binds to the antiapoptotic protein which displaces the effector and then promotes MOMP.
Modified from (Chipuk, Moldoveanu et al. 2010).
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1.5 Bcl-2 family regulation
BH3-only proteins are the major sensors for any cellular stress. BH3-only
proteins can be activated in a variety of ways, such as transcriptional
upregulation, proteolysis, or post-translational modifications (Figure 1.5). Noxa
and Puma can be induced transcriptionally by the tumor suppressor p53 in
response to DNA damage (Oda, Ohki et al. 2000; Nakano and Vousden 2001).
Bim is regulated transcriptionally by the class O forkhead box transcription
factor-3A (FOXO3A) in response to growth factor deprivation (Dijkers, Medema
et al. 2000). Bim can be also regulated at transcriptional level, where bim mRNA
is negatively regulated by the miRNA cluster miRNA-17-92 (Xiao, Srinivasan et
al. 2008). In healthy cells, Bim is sequestered away from the anti-apoptotic
proteins by binding to LC8 dynein light chain in the microtubule-associated
dynein motor complex (Puthalakath, Huang et al. 1999). Following a death signal,
Bim dissociates from the motor complex and translocates to neutralize Bcl-2 antiapoptotic activity. Moreover, phosphorylation of pro-apoptotic Bim by ERK1/2
on serine 69 promotes its degradation by the ubiquitin-proteasome pathway
(Luciano, Jacquel et al. 2003).
The BH3-only protein Bad is regulated by post-translational modification on
two phosphorylation sites, ser-112 and ser-136. The phosphorylated Bad is
sequestered in the cytosol by a 14-3-3 molecule that prevents interaction with
anti-apoptotic Bcl-xl (Zha, Harada et al. 1996). The survival signaling molecule
Akt has been shown to lead to phosphorylated Bad at ser-136 and inactivate its
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function, however, dephosphorylated Bad can neutralize Bcl-xl to promote
apoptosis following IL-3 deprivation (Datta, Dudek et al. 1997).
Interestingly, unlike other pro-apoptotic members, Bid undergoes a cleavage
mediated by caspase-8 (Li, Zhu et al. 1998) and this cleavage allows the buried
BH3 domain to be exposed. The cleaved Bid (tBid) can then translocate to the
mitochondria to promote apoptosis (Figure 1.5).
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Figure 1.5: Activation of BH3-only proteins. BH3-only proteins are activated in
a variety of ways, including proteolysis, post-translational modifications, or
transcriptional up regulation. Bid is activated by cleavage, whereas Bad is kept in
an inactive phosphorylated form bound to 14-3-3 in the cytoplasm. Following
growth factor/cytokine deprivation, Bad is activated by de-phosphorylation. Bim
is bound to the microtubules and released after cytokine deprivation. Puma and
Noxa are transcriptionally up regulated by p53 following DNA damage. The
activated BH3-only proteins can then translocate to the mitochondria where they
promote apoptosis by activating the effector proteins or by neutralizing the antiapoptotic proteins. Modified from (Gardner 2004).
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The anti-apoptotic protein Mcl-1 also undergoes several post-translational
modifications since it has a large N terminal that contains two sequences rich in
proline (P), glutamic acid (E), serine (S), and threonine (T), which mediate rapid
degradation or promote stability of the proteins (Gores and Kaufmann 2012).
These modifications are critical for determining whether Mcl-1 promotes or
prevents apoptosis. Mcl-1 protein has a unique feature that differentiates it from
other anti-apoptotic Bcl-2 family members: it has a short half-life estimated at less
than 1 hour (Stewart, Koss et al. 2010). The short half-life of Mcl-1 is due to
constitutive polyubiquitination and degradation by the proteasome. It has been
shown that following IL-3 withdrawal, Mcl-1 is phosphorylated on serine159 by
glycogen synthase kinase-3 (GSK-3) and thus accelerating ubiquitinylation and
degradation of Mcl-1 (Maurer, Charvet et al. 2006). Mcl-1 is ubiquitinylated by
MULE (Mcl-1 Ubiquitin Ligase E3) at five lysines of its N terminus (Zhong, Gao
et al. 2005). MULE contains a BH3 domain that binds to Mcl-1 and promotes its
degradation. FBW7 is another E3 ubiquitin ligase that has been recently identified
to promote Mcl-1 degradation (Inuzuka, Shaik et al. 2011). It has been reported
that removing ubiquitin groups conjugated to Mcl-1 by the deubiquitinase USP9X
was found to increase Mcl-1 stability and thus, promote cell survival (Schwickart,
Huang et al. 2010). USP9X binds Mcl-1 and removes the polyubiquitin chains
that flags Mcl-1 for proteasomal degradation, which results in high Mcl-1 levels.
Interestingly, Mcl-1 activity can be changed from anti-apoptotic to pro-apoptotic
activity during apoptosis following cleavage by caspase-3 at Asp127 and/or
Asp157 (Michels, O'Neill et al. 2004).
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Ubiquilin-1 (Ubqln1) has been identified to interact specifically with Bcl-b and
not with other anti-apoptotic proteins. Ubqln1 promotes Bcl-b protein
stabilization and re-localization from the mitochondria to the cytosol which leads
to more potent anti-apoptotic activity (Beverly, Lockwood et al. 2012).
The anti-apoptotic protein Bcl-2 can also be regulated by post-translational
modification; caspase-3 cleaves the carboxyl terminal at Asp34, which converts
the Bcl-2 phenotype from anti-apoptotic to pro-apoptotic (Cheng, Kirsch et al.
1997; Chen, Gong et al. 2000). This conformational change reveals the proapoptotic activity of Bcl-2. Moreover, binding the orphan nuclear receptor Nur77
to Bcl-2 causes a conformational change that leads to expose the buried BH3
domain of Bcl-2 (Lin, Kolluri et al. 2004). On the other hand, anti-apoptotic Bclxl and Bfl-1 genes are directly regulated by the transcription factors signal
transducer and activator of transcription (STAT3) and NF-kB (Grumont, Rourke
et al. 1999; Zong, Edelstein et al. 1999; Grad, Zeng et al. 2000).

1.6 Bcl-2 family and its physiological roles
Knockout mice studies have revealed the essential role of the Bcl-2 family in
embryogenesis and tissue homeostasis. Bcl-xl was found to be essential for
embryogenesis, neuronal cells, and hematopoietic cell survival (Motoyama, Wang
et al. 1995). It has been recently shown that Bcl-xl is also critical for lymphoma
development (Kelly, Grabow et al. 2011). Bcl-2-deficient mice show complete
embryonic

development,

however,
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they

have

defects

in

lymphocyte

differentiation and severe polycystic kidney disease (Veis, Sorenson et al. 1993).
Mcl-1 deletion was reported to be lethal due to the failure of embryonic
implantation (Rinkenberger, Horning et al. 2000), Mcl-1 was also found to be
critical for the development and survival of acute myeloid leukemia (AML) cells
(Glaser, Lee et al. 2012).
Bax knockout mice exhibit B-cells hyperplasia (Knudson, Tung et al. 1995),
whereas Bak-deficient mice have been reported to be developmentally normal.
Interestingly, Bak and Bax double knockout mice showed a huge accumulation of
hematopoietic cells due to lack of apoptosis (Lindsten, Ross et al. 2000).
Gene targeting studies have defined the essential functions of different BH3only members in mediating apoptosis. Bid has been reported to be a critical factor
for cell death initiated by death receptor Fas, as Bid-deficient mice were highly
resistant to Fas-induced apoptosis (Yin, Wang et al. 1999). In addition, deleted
Bim causes resistance to apoptosis induced by growth factor deprivation in a
broad range of cell types (Bouillet, Metcalf et al. 1999), whereas loss of Puma and
Noxa mediate resistance to DNA damage agents (Villunger, Michalak et al.
2003).

1.7 Bcl-2 family regulation in cancer
Blocking apoptosis is considered one of the hallmarks of cancer as impaired
apoptosis maintains cancer survival and progression (Hanahan and Weinberg
2011). Cancer cells block apoptosis either by promoting overexpression of the
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anti-apoptotic proteins or by downregulating the pro-apoptotic proteins. Both
increased levels of anti-apoptotic proteins or the loss of pro-apoptotic proteins are
associated with genetic alterations in many tumor malignancies. Chromosomal
translocations,

deletion,

additional

copy

numbers,

post-translational

modifications, or epigenetic alterations have been reported to modulate Bcl-2
family expression that can promote survival of cancer cells.
In follicular B-cell lymphoma, a high Bcl-2 expression level is associated with
(14;18) chromosomal translocations, which place the Bcl-2 gene on chromosome
18 under the control of an immunoglobulin heavy chain enhancer on chromosome
14, resulting in excessive Bcl-2 production though transcriptional regulation
(Tsujimoto, Cossman et al. 1985). High Bcl-2 levels have also been reported in
diffuse large B-cell lymphoma and chronic lymphocytic leukemia due to Bcl-2
gene amplification or hypomethylation of the Bcl-2 promoter (Hanada, Delia et
al. 1993; Monni, Joensuu et al. 1997). In addition, the single nucleotide
polymorphisms 938 C >A in the Bcl-2 promoter enhanced its binding activity and
resulted in high Bcl-2 levels in chronic lymphocytic leukemia cells (Nuckel, Frey
et al. 2007).
Preventing Bcl-2 pro-apoptotic activity of anti-apoptotic proteins can be a
strategy for blocking apoptosis in cancer cells. Mutation of the aspartic acid
residue required for caspase cleavage that changes Bcl-2 function from antiapoptotic to pro-apoptotic has been identified in human lymphoma (Cory, Huang
et al. 2003).
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Interestingly, the loss of endogenous microRNAs that normally repress antiapoptotic Bcl-2 protein expression can be a mechanism for elevated levels of
these anti-apoptotic proteins. MicroRNAs are short, noncoding RNAs of about
19–24 nt that bind to 3′ UTRs of target mRNAs and promote their degradation.
MiR-15a and miR-16-1 are located in a cluster at 13q14.3, which are frequently
deleted in CLL (Calin, Ferracin et al. 2005). Deletions of miR-15a and miR-16-1
result in high Bcl-2 expression.
In cancer cells, Mcl-1 undergoes post-translational modification to enhance
cell survival by increasing the rate of protein stability. Extracellular signalregulated kinases (ERK) activation promotes Mcl-1 phosphorylation at Thr163
and stabilization of the Mcl-1 protein (Domina, Vrana et al. 2004). The E3
ubiquitin ligase that targets phosphorylated Mcl-1 for degradation has been
recently identified as FBW7 (Inuzuka, Shaik et al. 2011). FBW7 is a E3 ubiquitin
ligase which controls Mcl-1 stability. FBW7 has tumor-suppressor activity, as
mutation or deletion of this gene resulted in a significant increase in Mcl-1 levels
in human ALL cell lines.
In a large study to analyze gene copy number in many cancer specimens, the
Mcl-1 genomic region has been found to be amplified in lung and breast cancers
(Beroukhim, Mermel et al. 2010). MiR-29 was found to negatively regulate Mcl1 expression and miR-29 loss is consequently associated with high Mcl-1 levels
(Mott, Kobayashi et al. 2007). Like Mcl-1, Bfl-1 protein has a short half-life,
which can be markedly increased by the mutation of C-terminal lysines 151,163,
and 172 to arginines (Fan, Simmons et al. 2010). These ubiquitination-resistant
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mutants show that Bfl-1 deubiquitination is critical for its tumor promotion
mechanism.
It has recently been reported that chromosomal translocation of the
transcription factor BACH2 gene on 6q15 to the second exon of Bcl-xl on 20q11
resulted in strong expression of Bcl-xl in the Burkitt lymphoma cell line BLUE-1
(Turkmen, Riehn et al. 2011).
Genetic alterations in pro-apoptotic genes have also been reported in many
cancers. These alterations can result in loss of the tumor suppressor function of
pro-apoptotic genes. Interestingly, p53 is the transcription factor for Bax, Bid,
Puma and Noxa; therefore, any deletion or mutation in the p53 gene will directly
affect the transcriptional levels of these genes (Miyashita and Reed 1995; Oda,
Ohki et al. 2000; Nakano and Vousden 2001). Bim function is reported to be lost
in hematological malignancies; for example, the 2q13 locus where the BIM gene
is located has been reported to be deleted in mantle cell lymphoma (Tagawa,
Karnan et al. 2005). Bim expression can also be regulated transcriptionally by
microRNA as gene amplification of miR-17 that negatively regulates Bim level is
observed in several human cancers (Ventura, Young et al. 2008). Mutations that
cause inactive Bax have been reported in colon cancer (Rampino, Yamamoto et
al. 1997). AKT pathway is known to be highly activated in many cancers. Upon
activation, AKT phosphorylates the pro-apoptotic protein Bad, which results in its
sequestration by 14-3-3 (Zha, Harada et al. 1996).
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1.8 Bcl-2 family and clinical response in cancer
Apoptosis is often impaired in cancer and can significantly limit the response
to conventional therapy. Resistance of tumor cells to radiation or chemotherapy
can be due to a defect in the apoptosis machinery. Increased anti-apoptotic protein
levels have been reported in many human malignancies and generally correlate
with aggressive tumors and chemotherapeutic resistance (Letai 2008). A high
Mcl-1 level has been correlated with chemoresistance in various haematopoietic
and lymphoid cancers, CLL (Kitada, Andersen et al. 1998) and multiple myeloma
(Derenne, Monia et al. 2002). Interestingly, resistance to 122 standard
chemotherapy agents was correlated with high Bcl-xl levels in 60 NCI cell lines
(Amundson, Myers et al. 2000). The resistance to a group of compounds that
repress Mcl-1 expression was correlated with high mRNA expression of Bcl-xl,
indicating that the patients-selection strategy for development of any Mcl-1
inhibitor in breast and non-small cells lung carcinoma (NSCLC) tumors should be
based on patients with low Bcl-xl expression (Wei, Margolin et al. 2012). High
Bfl-1 levels were also found to contribute to fludarabine resistance in CLL cells
(Olsson, Norberg et al. 2007).
Several studies have attempted to correlate Bcl-2 family expression and
response to treatments, which highlight the potential application of the Bcl-2
family as a marker for predicting clinical outcome. We have shown that the
relative expression of Mcl-1 and Bfl-1 to Bcl-2 predicts ABT-737 response in
hematological and solid malignancies (Al-Harbi, Hill et al. 2011). High levels of
Bcl-2 and low levels of Bax were associated with resistance to chlorambucil in
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CLL (Thomas, Pepper et al. 2000). Interestingly, It was found that patients with
highly primed cancer cells or a high apoptotic threshold exhibited superior
clinical response to chemotherapy (Ni Chonghaile, Sarosiek et al. 2011).

1.9 Targeting anti-apoptotic proteins by small molecule inhibitors
Most conventional cytotoxic therapies act primarily through p53 activation to
induce apoptosis, and this indirect effect may explain the poor response in
patients with p53 deletion. Thus, it can be concluded that there is a need to
develop a new generation of targeted therapies that mediate response through
direct activation of the apoptotic machinery. This could be a very promising
approach since most cancer cells are addicted to high expression of anti-apoptotic
proteins in order to maintain their survival and progression.
Obatoclax: A screen of a natural products library for Bcl-2 inhibitors identified
obatoclax as a molecular antagonist that binds to Bcl-2, Bcl-xl, Bcl-w, and Mcl-1
with low micromolar affinity (Perez-Galan, Roue et al. 2007). Obatoclax has
shown high anti-tumor activity through disruption of the Mcl-1:Bak interactions
(Li, Viallet et al. 2008). In contrast, another report showed that obatoclax has the
same anti-tumor activity in Bak/Bax double knockout mice as wild type cells, and
the anti tumor activity was similar in cells with both high and low anti-apoptotic
proteins levels (Lessene, Czabotar et al. 2008). This leads to the conclusion that
the cell death induced by the drug is not mediated by apoptosis and sensitivity to
the drug was not correlated to expression levels of anti-apoptotic Bcl-2 proteins.
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Gossypol: Another small molecule antagonist that targets anti-apoptotic proteins
is gossypol. It is a drug derived from the cotton plant and has shown high antitumor activity in several hematological malignancies, including lymphoma and
multiple myeloma cell lines, as well as in vivo models (Paoluzzi, Gonen et al.
2008); however, one major drawback of the drug is that its anti tumor activity
requires a high concentration (≈20µM), which it is difficult to achieve clinically.
ABT-737: Crystal structural studies have shown that the BH3 peptide is 16 to 20
amino acids in length and binds a hydrophobic pocket formed by the BH1, BH2
and BH3 domains on the surface of anti-apoptotic proteins (Muchmore, Sattler et
al. 1996; Sattler, Liang et al. 1997). This provides the platform for a new drug
discovery based on mimicking BH3 peptides that can be rational antagonists of
the anti-apoptotic proteins. Nuclear magnetic resonance (NMR)-based screening
and structure-based design structure methods were applied rationally to develop a
small molecule inhibitor that binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w,
and with low affinity to Mcl-1 and Bfl-1 (Oltersdorf, Elmore et al. 2005) (Figure
1.6). ABT-737 has maintained its high activity even in the presence of 10%
human serum with a minimum effect on normal primary cells derived from
healthy donors. As compared to seven anti-apoptotic protein inhibitors, ABT-737
was the only one to mediate cell death in a Bak/Bax-dependent manner (van
Delft, Wei et al. 2006).
We have recently shown that ABT-737 activity is based on relative expression
of Mcl-1 and Bfl-1 to Bcl-2 in hematological malignancies and small cell lung
carcinoma (Al-Harbi, Hill et al. 2011). This indicates that ABT-737 is a highly
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selective target. ABT-737 and its oral derivative compound navitoclax had a
marked cytotoxic effect as a single agent in a variety of tumor types, including
lymphoma and lung cancer when used within nanomolar range (Tse, Shoemaker
et al. 2008). Tumor volume was significantly reduced in small cell lung cancer
xenografts and haematological xenografts when treated with navitoclax (Tse,
Shoemaker et al. 2008). Recent clinical trials show that the drug is highly
effective with minimum off target-effects (Wilson, O'Connor et al. 2010; Gandhi,
Camidge et al. 2011; Roberts, Seymour et al. 2012).
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Figure 1.6: Interaction between anti-apoptotic protein Bcl-xl and ABT-737.
(A) Structure of ABT-737 binding to the hydrophobic pocket on the surface of
anti-apoptotic Bcl-xl protein. (B) ABT-737 chemical structure. Modified from
(Lessene, Czabotar et al. 2008).
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1.10 Bcl-2 family and Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the
Western world, and accounts for approximately 30% of leukemia cases in the
United States (Lee, Dixon et al. 1987). CLL is characterized by an excessive
accumulation of morphologically mature B lymphocytes in the blood, marrow,
and lymphatic tissues. Blocking apoptosis by high levels of anti-apoptotic
proteins is considered the hallmark of CLL. Interestingly, it has been reported that
high levels of Bcl-2 correlate with high white blood cell (WBC) counts in CLL
patients (Del Gaizo Moore, Brown et al. 2007). This leads to the conclusion that
high B-cell counts are more likely to be a result of decreased apoptosis rather than
of an increased in proliferation rate.
Clinical staging (Rai/Binet) in CLL is based on classification into three stages
(Bazargan, Tam et al. 2012): low stage (0) is characterized by lymphocytosis
located in the blood or bone marrow, intermediate stage (I, II) is a patient with
lymphocytosis and enlarged lymph nodes, liver, or spleen. High stage (III, IV): is
characterized by lymphocytosis and anemia (Hgb <11 g/dl), or lymphocytosis and
thrombocytopenia (platelet count <100,000/μl). This clinical staging system is
essential to estimate the tumor burden, however it is not useful in predicting
which patients in an early stage are likely to have an aggressive form of the
disease and a short survival rate. P53 deletion, ATM deletion or mutation have
been described to influence CLL prognosis and clinical response to DNAdamaging agents (Pleyer, Egle et al. 2009).
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1.11 Bcl-2 family interaction with non Bcl-2 family proteins
The anti-apoptotic Bcl-2 proteins have been reported to regulate another aspect
of cell death. Bcl-2 and Bcl-xl have been linked to autophagy. Autophagy is a
nonapoptotic cell death that is found to be suppressed by Bcl-2 and Bcl-xl
(Shimizu, Kanaseki et al. 2004). These proteins can bind to the tumor suppressor
beclin 1 (BECN1), which contains a BH3 domain, to inhibit autophagosome
formation (Oberstein, Jeffrey et al. 2007).

ATG12, which is an autophagic

protein, was recently reported to have a unique BH3-like motif that mediates
binding and inactivates the anti-apoptotic activity of Bcl-2 and Mcl-1 (Rubinstein,
Eisenstein et al. 2011).
The Bcl-2 proteins usually interact through the BH3 domain; however,
proteins without a distinct BH3 domain can interact with the Bcl-2 family. This
suggest that a BH3 domain may not be required to engage the Bcl-2 family
interaction where molecules containing a BH3-like domain may also mediate this
function (Chipuk, Moldoveanu et al. 2010). For example, cytosolic p53 has been
reported to interact with anti-apoptotic Bcl-2 protein and/or Bak and Bax.
Following genotoxic stress, p53 can promote apoptosis by localizing into the
mitochondria (Marchenko, Zaika et al. 2000). It has been shown that p53 is
sequestered by Bcl-xl in the cytosol, and this interaction can be disrupted by
Puma following genotoxic stress (Chipuk, Bouchier-Hayes et al. 2005). Recently,
three conserved hydrophobic residues (F19, W23 and L26) of p53 (SN15) peptide
have been identified to anchor into three hydrophobic pockets of Bcl-xl in a
similar manner as the BH3 peptide (Bharatham, Chi et al. 2011).
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CHAPTER II
AN ANTI-APOPTOTIC BCL-2 FAMILY EXPRESSION INDEX
PREDICTS THE RESPONSE OF CHRONIC LYMPHOCYTIC
LEUKEMIA TO ABT-737
Sayer Al-harbi et al, BLOOD, 29 SEPTEMBER 2011, VOLUME 118,
NUMBER 13
2.1 Abstract
The anti-apoptotic Bcl-2 proteins regulate lymphocyte survival and are
overexpressed in lymphoid malignancies, including CLL. The small molecule
inhibitor ABT-737 binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w but with
low affinity to Mcl-1, Bfl-1, and Bcl-b. The active analog of ABT-737, navitoclax
has shown a high therapeutic index in lymphoid malignancies; developing a
predictive marker for it would be clinically valuable for patient selection or choice
of drug combinations. Here we used RT-PCR as a highly sensitive and
quantitative assay to compare expression of anti-apoptotic Bcl-2 genes that are
known to be targeted by ABT-737. Our findings reveal that the relative ratio of
Mcl-1 and Bfl-1 to Bcl-2 expression provides a highly significant linear
correlation with ABT-737 sensitivity (r=0.6, P<0.001). In contrast, anti-apoptotic
transcript levels, used individually or in combination for high or low affinity
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ABT-737-binding proteins could not predict ABT-737 sensitivity. The (Mcl-1 +
Bfl-1)/Bcl-2 ratio was validated in a panel of leukemic cell lines subjected to
genetic and pharmacologic manipulations. Changes following ABT-737 treatment
included increased expression of Bfl-1 and Bcl-b that may contribute to treatment
resistance. This study defines a highly significant Bcl-2 expression index for
predicting

the

response

of
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CLL

to

ABT-737.

2.2 Introduction
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in
the Western World (Lee, Dixon et al. 1987). It is characterized by an expansion of
small mature B cells in the peripheral blood, lymph nodes, and bone marrow. The
standard of care for medically-fit patients involves sequential cycles of chemoimmunotherapy with the purine nucleoside analog fludarabine combined with
cyclophosphamide and the anti-CD20 monoclonal antibody rituximab (FCR)
(Hallek, Fischer et al. 2010; Robak, Dmoszynska et al. 2010).
The Bcl-2 family proteins regulate apoptosis primarily at the mitochondria
through the intrinsic apoptotic pathway (Del Gaizo Moore, Brown et al. 2007;
Letai 2008). These proteins are divided into three classes based on sequence
homology (Bcl-2 homology domains BH1 to BH4) and function (Adams and
Cory 2007; Deng, Carlson et al. 2007). The anti-apoptotic proteins that display
sequence homology in all BH1-BH4 domains are Bcl-2, Bcl-xl, Bcl-w, Mcl-1,
Bfl-1, and Bcl-b. The pro-apoptotic Bcl-2 family members are divided into
multidomain effectors (Bax and Bak containing BH1-BH3 domains) and the
BH3-only proteins (Bim, Puma, and Noxa). Increased expression of the antiapoptotic proteins represents the main factor that accounts for blocking the
intrinsic apoptosis pathway. This inhibition of apoptosis is accomplished by
sequestering pro-apoptotic proteins and thus preventing mitochondrial outer
membrane permeabilization (MOMP) (Tait and Green 2010), (Cheng, Wei et al.
2001; Willis, Chen et al. 2005; Certo, Del Gaizo Moore et al. 2006).
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Elevated levels of Bcl-2, Mcl-1, and Bcl-xl mRNA and protein are found in
many solid tumors and hematologic malignancies, including CLL (Gottardi,
Alfarano et al. 1996; Kitada, Andersen et al. 1998; Pepper, Hoy et al. 1998; Rust,
Harms et al. 2005; Stam, Den Boer et al. 2010). Importantly, Bcl-2 and Mcl-1
protein expression parallels their mRNA levels in diffuse large B-cell lymphoma
(DLBCL) and CLL (Shen, Iqbal et al. 2004; Veronese, Tournilhac et al. 2008). In
most cases of follicular lymphoma, high Bcl-2 levels could be caused by
chromosomal translocation t(14;18), which places the Bcl-2 gene under the
control of the IgH enhancer, leading to overproduction of the Bcl-2 transcript and
protein (Tsujimoto, Finger et al. 1984). In CLL, loss of microRNAs (miR) is
involved in regulation of the Bcl-2 family expression levels. 13q14 is the most
commonly detected chromosomal deletion in CLL that leads to loss of miR-15a
and miR-16, which causes increased Bcl-2 levels (Cimmino, Calin et al. 2005). In
addition, Mcl-1 can also be regulated by miRs, as miR-29 is known to negatively
regulate Mcl-1 levels (Calin, Ferracin et al. 2005). Several reports suggest that
Bcl-2 family proteins can be used as a predictive marker for the CLL response to
chemotherapy. The Mcl-1/Bax ratio was reported to correlate with chemoresistance to fludarabine and rituximab (Bannerji, Kitada et al. 2003; Pepper, Lin
et al. 2008). The Bcl-2/Bax ratio was also associated with resistance to
chlorambucil (Williamson, Kelly et al. 1998). In addition, Bcl-xl levels were
found to correlate with resistance to many standard chemotherapeutic agents in
the 60-tumor cell line NCI panel (Amundson, Myers et al. 2000).
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ABT-737 was developed as a rationally-designed, small-molecule inhibitor
that binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w but with much lower
affinity to Mcl-1, Bfl-1, and Bcl-b (Oltersdorf, Elmore et al. 2005). The orally
available Bcl-2-family inhibitor navitoclax (ABT-263) is now in clinical
development for lymphoid malignancies, including CLL, both as a single agent
and in combination with chemotherapy and/or monoclonal antibodies (Oltersdorf,
Elmore et al. 2005). Navitoclax showed a high therapeutic index in drug-resistant
lymphoid malignancies with low incidence of off-target toxic effects in a phase 1
dose-escalation study (Wilson, O'Connor et al. 2010). Moreover, preliminary
efficacy data from a phase I study with navitoclax (ABT-263) in patients with
small cell lung carcinoma (SCLC) and other solid tumors are encouraging as they
show that the drug is safe and well-tollerated (Gandhi, Camidge et al. 2011).
ABT-737 induces apoptosis in primary follicular lymphoma, CLL, acute myeloid
leukemia, and solid tumor cells (Oltersdorf, Elmore et al. 2005; Konopleva,
Contractor et al. 2006; Del Gaizo Moore, Brown et al. 2007). Interestingly, tumor
cell lines tested for ABT-737 response in cell culture have shown similar activity
in xenografts derived from the same cell lines in vivo (Oltersdorf, Elmore et al.
2005; Hann, Daniel et al. 2008).
Sensitivity to ABT-737 is thought to depend on a Bcl-2 complex enriched for
Bim (Del Gaizo Moore, Brown et al. 2007; Deng, Carlson et al. 2007). High
levels of Mcl-1 were also suggested to account for ABT-737 resistance mostly
based on cell line studies (Konopleva, Contractor et al. 2006; van Delft, Wei et al.
2006; Chen, Dai et al. 2007). In contrast, other studies report that there is no
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correlation between Mcl-1 expression and the response to ABT-737 in primary
CLL and in acute lymphoblastic leukemia xenografts (Del Gaizo Moore, Brown
et al. 2007; Mason, Khaw et al. 2009; Vogler, Butterworth et al. 2009; High,
Szymanska et al. 2010). Moreover, the ratios of Bcl-2/Bim, Bcl-2/Bax, Mcl1/Bim, or Mcl-1/Bax could not predict sensitivity to ABT-737 in primary CLL
(Mason, Khaw et al. 2009). Interestingly, long-term exposure to ABT-737
resulted in increased levels of both RNA and protein levels of Mcl-1 and Bfl-1
and development of resistance in lymphoma cell lines that were initially sensitive
(Yecies, Carlson et al. 2010).
There are currently no satisfactory predictive markers for the wide range of
response to ABT-737 in primary lymphoid cells. Developing a predictive index
for ABT-737 response may help in patient selection or choice of drug
combinations. In this study we examined whether quantifying expression of all
anti-apoptotic Bcl-2 family transcripts whose encoded proteins are known to be
targeted by ABT-737 could be used to identify a gene expression index that
predicts ABT-737 sensitivity. Here, we used a highly sensitive and quantitative
real-time (RT-PCR) assay to examine expression of six anti-apoptotic Bcl-2
family genes. We defined the relative expression of (Mcl-1 + Bfl-1)/Bcl-2 as the
most significant predictive marker for the response of primary CLL and leukemic
cell lines to ABT-737 treatment.
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2.3 Methods
2.3.1 Cell culture
Peripheral blood samples from 57 patients with CLL and six healthy donors
were obtained with the patients’ informed consent according to protocols
approved by the institutional review board (IRB) according to the Declaration of
Helsinki. All primary CLL cells were freshly processed without freezing.
Lymphocytes were purified by Ficoll-Paque PLUS (Amersham Biosciences,
Piscataway, NJ) gradient centrifugation. Cells were washed twice in media and
cultured at a density of 1 х 106 cells/ml in RPMI-1640 medium supplemented
with 5% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), Lglutamine (Invitrogen, Carlsbad, CA), and 100 units/ml penicillin-streptomycin
(Gibco BRL, Gaithersburg, MD). Primary CLL cells were treated for 18 hours
with ABT-737 at 50 nM, a concentration previously shown to be effective in most
primary CLL patients tested (Mason, Khaw et al. 2009). Nine leukemic cell lines
were used in the study: (i) three CLL (Mec-1, Mec-2, and PTA-3920), (ii) two
Pre-B (Nalm-6 and Reh), two B-cell-derived (NCI-H929 and IM-9), and two Tcell-derived (Jurkat and Molt-4). These cell lines were obtained from the
American Type Culture Collection (ATCC; Manassas, VA), with the exception of
Mec-1 and Mec-2, which were a gift from Dr. Y. Saunthararajah (Cleveland
Clinic). The cell lines, CLL primary cells, and human lymphocytes obtained from
healthy donors were all cultured under similar conditions. ABT-737 was obtained
from Abbott Laboratories (Abbott Park, IL).
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2.3.2 Purification of lymphocytes from healthy donors
Highly purified lymphocytes were obtained using the Gambro ElutraTM Cell
Separation System. Following the apheresis procedure, cells were washed in a
saline/tricitrasol solution prior to elutriation. Cell composition was verified on
Cell Dyn 3700 (Abbott Diagnostics, Abbott Park, IL) prior to elutriation. Cells
were separated using a continuous countercurrent buffer flow of Hank’s Balanced
Salt

Solution

(Lonza

BioWhittaker,

Switzerland),

with

simultaneous

centrifugation, using the Caridian Elutra Cell Separation System (CaridianBCT,
Lakewood, CO). Fractions were centrifuged at 2500 rpm for 5 min at 4C° and
pooled to concentrate the product.

Purity of the final combined product as

determined on the Cell Dyn 3700 was >97%.

2.3.3 Flow cytometry
Cell death was assessed by phosphatidylserine (PS) externalization as we have
previously described (Chen, Gong et al. 2001). After 18 hours of culture, primary
CLL cells and established cell lines were stained with fluorescein-conjugated
Annexin V (BD Biosciences, San Jose, CA) and propidium iodide (PI) and
analyzed on a BD FACSCalibur flow cytometer. Raw data were analyzed using
the CellQuest software. Results were normalized to survival of untreated cells.
Spontaneous cell death in freshly derived CLL cells was less than 30%.
Flow cytometric immunophenotyping was performed at Cleveland Clinic as part
of the diagnostic evaluation on a FACSCanto instrument (BD Biosciences, San
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Jose, CA). Each of these flow cytometric evaluations was performed using
fluorescently labeled monoclonal antibodies against CD38 and ZAP70. Staining
protocols were standard lyses/washing protocols, as previously described (Chen,
Gong et al. 2001).

2.3.4 FISH
A dual-color probe for CLL PANEL 1 (ATM/p53) and a tri-color probe for
CLL PANEL 2 (D13S319/13q34/CEP12), (Abbott Molecular, Inc., Des Plaines,
IL) were used. Fluorescence in situ hybridization (FISH) was performed
according to the manufacturer’s instructions. The p53 probe corresponds to
chromosomal region 17p13.1. The ATM probe corresponds to chromosome
region 11q22.3. Chromosomal region 13q34 was detected by the D13S319 probe.
Trisomy of chromosome 12 was detected by the CEP12 probe. Abnormalities of
17p present in ≥ 15% of nucleated cells were considered positive. Abnormalities
of other probes (13q34, CEP12, and ATM) present in ≥ 10% of nucleated cells
were considered positive.

2.3.5 Pharmacologic and genetic manipulation of Mcl-1 and Bfl-1
Flavopiridol was obtained from Sanofi-Aventis though the NCI Cancer
Therapy Evaluation Program. All the ABT-737-resistant cell lines: Mec-1, Mec-2,
PTA-3920, NCI-H929, and Nalm-6 were treated with flavopiridol for 4 hours
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with a 300 nM concentration, which was reported to be effective in decreasing
Mcl-1 levels (Yecies, Carlson et al. 2010). After the drug was removed, cells were
then treated with 100 nM of ABT-737 (EC50 of sensitive cell lines) for 18 hours.
Mcl-1 and Bfl-1 knockdown in Mec-1 cells was achieved by shRNAs
delivered with the use of lentiviral-mediated transduction. Cell populations with
stable expression of shMcl-1, shBfl-1, and as control a scrambled shRNA
(shControl) were selected by puromycin (Sigma). Lentiviral particles targeting
three different regions of Mcl-1 (sc-35877-V), and Bfl-1 (sc-37285-V), and the
scrambled shRNA (sc-108080) were obtained from Santa Cruz, CA.

2.3.6 RNA isolation and quantitative RT-PCR
Total RNA was isolated using the Trizol method (Invitrogen). Two µg of RNA
were reverse transcribed using the TaqMan reverse transcription kit and amplified
using the SYBR Green Master Mix (Applied Biosystems, N8080234 and
4309155) and examined on a 7500 Real-Time PCR system (Applied Biosystems).
Quantitative, real-time reverse transcription polymerase chain reaction (RT-PCR)
was performed as we have described previously (Crosby, Jacobberger et al. 2007)
using the following specific primers: Bcl-B: 5’-GCTGGGATGGCTTTTGTCA-3’
(forward) and 5’- GCCTGGACCAGCTGTTTTCTC-3’ (reverse); Bcl-w: 5’ACCCCAGGCTCAGCCCAACA-3’

(forward)

and

5’-

CAGCACACAGTGCAGCCCCA-3’ (reverse); Bcl-2 (Stecca, Mas et al. 2007):
5’-GGAGGATTGTGGCCTTCTTT-3’
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(forward)

and

5’-

GGAGGATTGTGGCCTTCTTT-3’ (reverse); Bcl-xl (Aerbajinai, Giattina et al.
2003):

5’-GGATGGCCACTTACCTGA-3’

(forward)

and

5’-

GCCGTACAGTTCCACAAAGG-3’ (reverse); Bfl-1 (Yecies, Carlson et al.
2010):

5’-TTACAGGCTGGCTCAGGACT-3’

(forward)

and

5’-

AGCACTCTGGACGTTTTGCT-3’ (reverse); Mcl-1 (Yecies, Carlson et al.
2010):

ATGCTTCGGAAACTGGACAT-3’

(forward)

and

5’-

TCCTGATGCCACCTTCTAGG-3’ (reverse); Bim (Nordigarden, Kraft et al.
2009):

5’-TGGCAAAGCAACCTTCTGATG-3’

(forward)

and

5’-

GCAGGCTGCAATTGTCTACCT-3’ (reverse); Noxa (Jiang, Lucas et al. 2008):
5’-TGGAAGTCGAGTGTGCTACTCAA-3’ (forward) and
5’-CAGAAGAGTTTGGATATCAGATTCAGA-3’

(reverse);

Puma

(Jiang,

Lucas et al. 2008): 5’-GCATGCCTGCCTCACCTT-3’ (forward) and 5’TCACACGTCGCTCTCTCTAAACC-3’ (reverse); Actin (Yecies, Carlson et al.
2010):

5’-AGAAAATCTGGCACCACACC-3’

(forward)

and

5’-

AGAGGCGTACAGGGATAGCA-3’ (reverse). Each experiment was repeated
twice. The Bcl-b and Bcl-w primers were designed using the Primer Express
(Applied Biosystems), and Primer 3 (LIST sequence) software, respectively. A
lymphocyte sample set was used to establish a baseline comparison between
mRNA levels in CLL and healthy donors. The extent of knockdown of Mcl-1 and
Bfl-1 levels was determined by quantitative RT-PCR using the above primers as
well as those suggested by the manufacturer (Santa Cruz, CA) for Mcl-1 (sc35877-PR) and Bfl-1 (sc-37285-PR).
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2.3.7 Statistical analysis
Baseline characteristics were grouped by in vitro culture sensitivity to ABT737 treatment and compared between the resulting two groups using Fisher’s
exact test or t-test. Spearman correlation was used to assess the strength and
direction of association between post-treatment cell viability and each Bcl-2
family member individually or in combination. The Cohen interpretation of
correlation (r) indicates that when r<0.3 it represents weak correlation, 0.3-0.5 is
moderate, and >0.5 is strong. Three groups were defined based on cell viability.
Expression of Bcl-2 family members, individually or in combination were
compared among the three groups using the Kruskal-Wallis test. Pairwise
comparisons between groups were performed using the Wilcoxon rank sum test.
A Bonferroni correction was used for pairwise comparisons. Pre- to posttreatment changes in Bcl-2 family transcripts were assessed using the Wilcoxon
signed rank test. All statistical tests were two-sided. For pairwise comparisons,
p<0.017 was used to indicate statistical significance. For all other comparisons,
p<0.05 was used to indicate statistical significance.
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2.4 Results
2.4.1 Primary CLL cells display differential sensitivity to ABT-737
To determine the sensitivity of CLL to ABT-737, freshly isolated primary CLL
cells derived from the peripheral blood of patients were examined by flow
cytometry for Annexin V staining as a cell death assay (Chen, Gong et al. 2001).
The majority of primary CLL samples underwent apoptosis after treatment with
ABT-737; however, there was a wide range of sensitivity, in agreement with
earlier reports (Figure 2.1A) (Oltersdorf, Elmore et al. 2005; Mason, Khaw et al.
2009). Based on their response, primary CLL samples from 57 patients could be
classified into three groups: (i) A sensitive group (33/57 cases, 57.8%) with cell
viability less than 40%, (ii) An intermediate group (15/57, 26.3%) with viability
of 40-65%, and (iii) A resistant group (9/57, 15.7%) with viability > 65%.
Increasing the time exposures of ABT-737 from 18 to 36 hours did not change the
sensitivity groups for the CLL samples (data not shown).

2.4.2 Baseline characteristics of patients with ABT-737 sensitive and resistant
CLL are similar
Baseline characteristics of CLL patients in this study (Table 2.1, Figure 2.2AB) were grouped by in vitro culture sensitivity to ABT-737 treatment. The median
age was similar for both groups. The majority of patients in both the ABT-737
sensitive and resistant groups had early stage (Rai 0, I, or II) disease and had not
been treated for their CLL prior to ABT-737 testing. The proportion of cases
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positive for ZAP70 and CD38 by flow cytometry and commonly detected
chromosomal abnormalities by fluorescence in situ hybridization (FISH) testing
that are indicated do not differ significantly between the ABT-737 sensitive and
resistant groups. ABT-737 sensitivity was similar for patients with early versus
advanced stage of the disease (P = 0.7) (Figure 2.2A). It was also similar for
common prognostic markers for CLL, such as ZAP70 (P = 0.72) or CD38 (P =
0.54) expression (Del Poeta, Maurillo et al. 2001; Rassenti, Huynh et al. 2004)
(Figure 2.2B), prior treatment, 17p deletion (p53) (Dohner, Stilgenbauer et al.
2000; Seiler, Dohner et al. 2006), or 13q14 deletion (Table 2.1), consistent with
previous findings (Del Gaizo Moore, Brown et al. 2007; Mason, Khaw et al.
2009; Vogler, Butterworth et al. 2009).
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Table 2.1: Patients characteristics
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Figure 2.1. A wide-range of responses to ABT-737 in primary CLL. Primary
CLL cells derived from 57 patients were incubated with ABT-737 (50 nM) for 18
hours. Cell survival was assessed by Annexin V/FITC binding, as determined by
flow cytometric analysis. Values are normalized to survival of untreated cells and
each data point represents one CLL patient. Based on cell viability data, the
response to ABT-737 was classified into: resistant (> 65%), intermediate (40% to
65%), and sensitive (< 40%).
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Figure 2.2. Responses to ABT-737 in primary CLL is independent of known
prognostic markers. The proportion of CLL patients in the resistant/intermediate
and sensitive groups respectively was examined with regard to the common CLL
prognostic markers: (A) Rai stage and (B) ZAP70, CD38 expression. P-values are
shown for comparison of groups.
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2.4.3 Lack of correlation between expression of Bcl-2 family members,
individually or combined, and their response to ABT-737
To investigate the possible contribution of Bcl-2 family members to ABT-737
response, we determined their expression levels. Of the nine Bcl-2 family
members that we have examined, we focused first on the six anti-apoptotic
members since ABT-737 was designed to target anti-apoptotic proteins and we
reasoned that their differential expression could define ABT-737 sensitivity.
Expression of each individual anti-apoptotic transcript or their combinations in
untreated CLL was plotted against cell viability following ABT-737 treatment
(Figure 2.3). No linear correlation was found between expression levels of any
single anti-apoptotic Bcl-2 family member (r < 0.3, P > 0.05) or their
combination (r < 0.3, P > 0.05), considering those with either high affinity (Bcl-2,
Bcl-w, and Bcl-xl) or those with low affinity (Mcl-1, Bfl-1, and Mc-1) to ABT737 (Figure 2.3). Next, we examined the expression of pro-apoptotic BH3-only
Bcl-2 family members Noxa, Bim, and Puma. Their mRNA levels were relatively
high in most of the tested CLL (data not shown). Nevertheless, no significant
correlation was found between expression levels of any of these pro-apoptotic
Bcl-2 family members, taken individually (r < 0.3, P > 0.05) or in combination (r
< 0.3, P > 0.05) and ABT-737 sensitivity.
Moreover, the six mRNAs were expressed at relatively similar levels in all the
healthy donors when they normalized to each other (Figure 2.4A). However,
normalizing all anti-apoptotic Bcl-2 family to β-actin revealed that Mcl-1 levels
were more abundant in normal lymphocytes compared to Bfl-1, Bcl-b, and Bcl-w,
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which were expressed at very low levels ((Figure 2.4b), note logarithmic scale
used to accommodate these large differences). In contrast, Bcl-b, Bfl-1, and Bcl-w
were highly upregulated compared to Mcl-1 in primary CLL.

47

48

Figure 2.3. Lack of correlation between mRNA expressions of anti-apoptotic
Bcl-2 family members, individually or combined, and response to ABT-737.
Quantitative RT-PCR was used to study anti-apoptotic Bcl-2 family mRNAs.
Expression values of each anti-apoptotic transcript or their combinations were
plotted against cell viability following ABT-737 treatment. RNA expression for
each transcript was normalized to that obtained in lymphocytes isolated from six
healthy donors. (A) Bcl-2, (B) Mcl-1, (C) Bfl-1, (D) Bcl-b, (E) Bcl-xl, (F) Bcl-w,
(G) Bcl-2 + Bcl-xl + Bcl-w, and (H) Mcl-1 + Bfl-1 + Bcl-b expression. Spearman
correlation (r) and P-values are shown.
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2.4.4 An anti-apoptotic Bcl-2 family index predicts ABT-737 sensitivity
Because each anti-apoptotic transcript was expressed at different basal levels
in the lymphocytes from healthy donors (Figure 2.4B), we next standardized the
expression of the six mRNAs to one basal level to provide a better method of
comparison in CLL cells. Normalization to β-actin revealed the most abundant
anti-apoptotic determinants in untreated primary CLL (Figure 2.5). This approach
guided us to identify the critical determinants of the ABT-737 sensitivity. The
expression levels of Mcl-1, Bcl-2, and Bfl-1 were much higher compared to those
of Bcl-xl and Bcl-w. The sensitive group had the highest levels of Bcl-2 as
compared to expression of Mcl-1 and Bfl-1. The index mean was 0.45 for Bcl-2,
0.40 for Mcl-1, and 0.21 for Bfl-1. In contrast, compared to Bcl-2, the
intermediate group had relatively higher levels of Mcl-1 and Bfl-1, while the
resistant group had much higher levels of Mcl-1 and Bfl-1. In the intermediate
group, the index mean was 0.25 for Bcl-2, 0.37 for Mcl-1, and 0.21 for Bfl-1. In
the resistant group, the index mean was 0.21 for Bcl-2, 0.48 for Mcl-1, and 0.19
for Bfl-1. Next, we examined the expression of pro-apoptotic BH3-only Bcl-2
family members Noxa, Bim, and Puma. Noxa levels were the highest compared to
those of Bim and Puma in the CLL samples examined (data not shown). Thus
Noxa levels were 3.5 and 6 fold higher than those of Bim and Puma, respectively
(data not shown).
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Figure 2.4. Bcl-2 family mRNA expression in lymphocytes isolated from
healthy donors. (A) mRNA levels of Bcl-2 family members determined by
quantitative RT-PCR normalized to those of the first healthy donor show similar
expression for each Bcl-2 family transcript. (B) Bcl-2 family members have
different basal levels normalized to β-actin. Note the logarithmic scale used to
reveal the large differences in the expression levels.
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Figure 2.5. Anti-apoptotic Bcl-2 family mRNA levels in ABT-737 sensitive,
intermediate, and resistant CLL groups. RNA expression of anti-apoptotic Bcl2 family members, as determined by quantitative RT-PCR, was normalized to βactin for each CLL patient sample. Bcl-2, Mcl-1, and Bfl-1 levels were more
abundant than those of Bcl-b, Bcl-xl, and Bcl-w in primary CLL. (A) The
sensitive group. (B) The intermediate group. (C) The resistant group. Mean values
are shown.
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In order to define an anti-apoptotic gene expression index predictive of ABT737 sensitivity, we plotted several combinations of genes relative to cell viability.
The relative ratio of Mcl-1 and Bfl-1 to Bcl-2 expression provided the best linear
correlation with ABT-737 sensitivity (r = 0.6, P < 0.001) (Figure 2.6A). By
comparison, the relative ratios of Mcl-1/Bcl-2 (Figure 2.6B) or Bfl-1/Bcl-2
(Figure 2.6C) showed a less robust linear correlation: (r = 0.45, P < 0.001), (r =
0.28, P= 0.030), respectively. The relative ratio of Bcl-b/Bcl-2 (Figure 2.6D)
showed no significant correlation (r = 0.16, P = 0.22). Including Bcl-b, Bcl-xl,
(Figure 2.6E-F), or Bcl-w (data not shown) into the (Mcl-1 + Bfl-1)/Bcl-2 model
had no significant effect on this correlation. The different ratios of anti-apoptotic
Bcl-2 family mRNAs were determined in the resistant, intermediate, and sensitive
groups (Figure 2.7). Of the different anti-apoptotic Bcl-2 family combinations
evaluated, (Mcl-1 + Bfl-1)/Bcl-2 provided the highest predictive value for the
ABT-737 response in CLL (Figure 2.7A), with P < 0.001 among all the three
groups. In the sensitive class (average cell viability 26.2%), the average ratio of
(Mcl-1 + Bfl-1)/Bcl-2 was 1.67. For the intermediate class (average cell viability
53.5%), the average ratio was 2.3. In the resistant class (average cell viability,
76.3), the average ratio was 3.3 (Table 2.2).
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Table 2.2: The (Mcl-1/Bfl-1)/Bcl-2 index in CLL and SCLC cell lines
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Figure 2.6. (Mcl-1 + Bfl-1)/Bcl-2 provides the most significant linear
correlation for sensitivity to ABT-737. Cell viability after ABT-737 treatment
was plotted against: (A) (Mcl-1+Bfl-1)/Bcl-2, (B) Mcl-1/Bcl-2, (C) Bfl-1/Bcl-2,
(D) Bcl-b/Bcl-2, (E) (Mcl-1 + Bfl-1 + Bcl-b)/Bcl-2, and

(F) (Mcl-1+Bfl-

1)/(Bcl2+Bcl-xl) ratios. Spearman correlation (r) and P-values are shown.
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Figure 2.7. The relative ratio of (Mcl-1 + Bfl-1)/Bcl-2 represents the most
informative predictive marker for the ABT-737 sensitivity. Relative
expression values for: (A) (Mcl-1 + Bfl-1) / Bcl-2, (B) Mcl-1/Bc-l2, (C) Bfl1/Bcl-2, (D) Bcl-b / Bcl-2, (E) (Mcl-1 + Bfl-1 + Bcl-b)/Bcl-2, and (F) (Mcl-1 +
Bfl-1)/(Bcl-2 + Bcl-xl), (Mcl-1 + Bfl-1)/Bcl-2 are the most significant among the
sensitive, intermediate, and resistant groups. P-values are indicated for
comparison between groups.
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2.4.5 The (Mcl-1 + Bfl-1) / Bcl-2 ratio is predictive of ABT-737 response in
leukemic and lung carcinoma cells
To further address the generality of our predictive model in leukemic cells, the
(Mcl-1 + Bfl-1) / Bcl-2 ratio was determined in a panel of leukemic tumor cell
lines (Table 2.3), (Figure 2.8). Of the nine cell lines tested, five (NCI-H929,
Nalm-6, Mec-1, Mec-2, and PTA-3920) were most resistant to ABT-737. They all
had a very high (Mcl-1 + Bfl-1) / Bcl-2 ratio, ranging from 6.4 to 17.5, with EC50
> 1000 nM. Two other cell lines, Reh and Molt-4 displayed an intermediate
sensitivity to ABT-737 (EC50= 300 and 400) having a ratio of 2.5 and 2.3,
respectively. IM-9 and Jurkat were the most sensitive (EC50 ≤100 nM) and had
ratios of 1.2 and 1.8, respectively (Table 2.3). These data indicate that the (Mcl-1
+ Bfl-1) / Bcl-2 ratio is predictive for the ABT-737 response in a broad range of
leukemic tumor cells, both primary and established.
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Table 2.3: The (Mcl-1 + Bfl-1) / Bcl-2 ratio in leukemic cell lines

59

60

Figure 2.8. Relative expression of Bcl-2, Mcl-1, and Bfl-1 in a panel of
leukemic cell lines. Bcl-2, Mcl-1, and Bfl-1 mRNA expression relative to β-actin
in (A) NCI-H929, (B) Nalm-6, (C) Mec-1, (D) Mec-2, (E) PTA-3920, (F) Reh,
(G) Molt-4, (H) Jurkat, and (I) IM-9 cells.
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Next, we tested if our model can also be applied to cancer types other than of
hematological origin. Small cell lung carcinoma (SCLC) is a solid tumor that has
been reported to have a high expression level of anti-apoptotic proteins, such as
Bcl-2. As navitoclax (ABT-263) is evaluated in clinical trials in SCLC patients,
we reasoned that it would be informative to test whether our model can predict
ABT-737 response in SCLC cell lines. By using ONCOMINE (Rhodes, Yu et al.
2004) as a cancer microarray database aimed to facilitate discovery from genomewide expression analyses, we applied our model in SCLC cell lines previously
categorized as ABT-737 resistant, intermediate, and sensitive groups (Olejniczak,
Van Sant et al. 2007). We found that in the sensitive group the average ratio of
Mcl-1 and Bfl-1 to Bcl-2 was 1.7, with the intermediate and resistant groups
having a ratio of 2.1 and 2.8, respectively (Table 2.2). Interestingly, these ratios
were very close and consistent with our findings in CLL patients. Of the different
anti-apoptotic Bcl-2 family combinations evaluated, the (Mcl-1 + Bfl-1) /Bcl-2
ratio provided the highest predictive value for ABT-737 response in SCLC
(r=0.73, P < 0.001) (Figure 2.9).
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Figure 2.9. The (Mcl-1 + Bfl-1)/Bcl-2 represents the most significant linear
correlation for sensitivity to ABT-737 in small cells lung carcinoma (SCLC).
SCLC cell lines with a wide range of response (resistant, intermediate, and
sensitive) to ABT-737 were plotted against: (A) (Mcl-1+Bfl-1)/Bcl-2, (B) Mcl1/Bcl-2,

(C)

Bcl-2,

(D)

(Mcl-1+Bfl-1)/(Bcl-2+Bcl-xl)

ratios.

Spearman

correlation (r) and P-values are shown. The Olejniczak dataset was used as
extracted from the ONCOMINE database (Rhodes, Yu et al. 2004).
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2.4.6 Decreased Mcl-1 and/or Bfl-1 levels enhance ABT-737 response in
resistant CLL cell lines
The five cell lines that we found to be highly resistant to ABT-737 had also a
high ratio of Mcl-1 and Bfl-1 to Bcl-2. We examined whether a decrease in Mcl-1
and/or Bfl-1 levels by a clinically relevant approach may improve ABT-737
response in resistant cell lines. Flavopiridol, which as a CDK9 inhibitor was
shown to decrease Mcl-1 at transcriptional level, also demonstrated a high
response rate in a phase II clinical trials in relapsed CLL patients (Lin, Ruppert et
al. 2009). All ABT-737 resistant cell lines were treated with flavopiridol and then
the Bcl-2, Mcl-1, and Bfl-1 levels were determined by quantitative RT-PCR
(Figure 2.10A; only data for CLL cell lines are shown). A four-hour flavopiridol
treatment decreased Mcl-1 and Bfl-1 levels, with little effect on Bcl-2 levels.
Following pre-treatment with flavopiridol, the (Mcl-1 + Bfl-1)/ Bcl-2 predictive
index values changed in all five ABT-737 resistant cell lines, shifting from highly
resistant to an index similar to what we have established for the sensitive CLL
group (Table 2.4). To determined whether this shift of the (Mcl-1 + Bfl-1) / Bcl-2
ratio by flavopiridol can convert the resistant cell lines to the sensitive group.
Following flavopiridol pre-treatment and removal, cells were treated with ABT737 for 18 hours (Figure 2.10B). There was a significant increase in cell death
when cells were pretreated with flavopiridol prior to ABT-737 treatment as
compared to single treatments with ABT-737 or flavopiridol for 18 hours (data for
NCI-H929 and Nalm-6 are not shown).
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Figure 2.10. Flavopiridol decrease Mcl-1 and Bfl-1 levels and increase the
response to ABT-737 in resistant CLL cell lines. (A) Mec-1, Mec-2, and PTA
CLL cells were treated with flavopiridol for four hours and then Bcl-2, Mcl-1 and
Bfl-1 levels were assessed by quantitative RT-PCR. (B) Mec-1, Mec-2 and PTA3920 were treated with flavopiridol for four hours, then the drug was removed and
cells were cultured without or with ABT-737(100 nM) for an additional 18 hours.
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Cell viability was assayed by annexin-V–FITC and PI staining and analyzed by
flow cytometry. Values are normalized to untreated cells and DMSO treatment
served as a negative control. P values were determined by the 2-tailed t-test. The
graphs presented are representative of two independent experiments with data
shown as mean

s.d.
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Table 2.4. The (Mcl-1+Bfl-1)/Bcl-2 in ABT-737–resistant cell lines after
treatment with flavopiridol for 4 hours.
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To further validate the pharmacologic inhibitor data, we applied a targeted
genetic approach for reducing Mcl-1 or Bfl-1, using shRNAs transduced with
lentivirus particles. Mec-1 was chosen since it is a highly ABT-737-resistant CLL
cell line that has high Mcl-1 and Bfl-1 levels. Examining knockdown of Mcl-1
and Bfl-1 by quantitative RT-PCR indicated an ~ 50% and 45% reduction in Mcl1 and Bfl-1 levels in shMcl-1 and shBfl-1-expressing Mec-1 cells, respectively
(Figure 2.11A). Estimating the index in these two cell lines indicated that
knockdown of Mcl-1 or Bfl-1 by shRNA reduced the index from 9.6 in parental
cells to 3.4 in shMcl-1 and 3.8 in shBfl-1-expressing Mec-1 cells, respectively.
Treating shMcl-1 and shBfl-1-expressing cells with ABT-737 increased cell death
significantly as compared to parental Mec-1 cell or those expressing as a control
scrambled shRNA (Figure 2.11B).
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Figure 2.11. ShRNA decrease Mcl-1 and Bfl-1 levels and increase the
response to ABT-737 in resistant CLL cell lines. (A) Quantitative RT-PCR
analyses of Bcl-2, Mcl-1, and Bfl-1 levels in Mec-1 parental, shMcl-1, shBfl-1,
and as a control, scrambled shRNA (shControl)-expressing cells. (B) Mec-1
parental, shControl, shMcl-1, and shBfl-1-expressing cells were treated with
ABT-737 (1000 nM) for 18 hours. Cell viability was assayed by annexin-V–FITC
and PI staining and analyzed by flow cytometry. Values are normalized to
untreated cells and DMSO treatment served as a negative control. P values were
determined by the 2-tailed t-test. The graphs presented are representative of two
independent experiments with data shown as mean
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s.d.

2.4.7 Modulation of anti-apoptotic Bcl-2 family mRNA expression following
ABT-737 treatment
As chemotherapeutics are known to modulate the expression of Bcl-2 family
members in hematologic tumors, we next examined the changes in expression of
anti-apoptotic Bcl-2 family mRNAs after ABT-737 treatment. In most primary
CLL samples tested there was a significant decrease in Bcl-2 (P < 0.001) and
Mcl-1 (P = 0.003) mRNA expression (Figure 2.12 A-B). In contrast, Bfl-1, Bcl-b,
and Bcl-w expression levels were highly upregulated following ABT-737
treatment (Figure 2.12 C-E). Bfl-1 levels were upregulated 9-fold, (P < 0.001),
with Bcl-w levels increased 6.5-fold (P < 0.001). Bcl-b levels were increased
more than 10-fold following ABT-737 treatment (P < 0.001). There were no
significant changes in Bcl-xl levels (P = 0.26) (Figure 2.12 F).
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Figure 2.12. Changes in the levels of anti-apoptotic Bcl-2 family transcripts
following ABT-737 treatment. Changes in mRNA expression levels of antiapoptotic Bcl-2 family proteins after treatment with ABT-737 (50 nM) for 18
hours. Expression was determined by quantitative RT-PCR to compare fold
difference in expression to levels prior to treatment that were normalized to those
found in lymphocytes isolated from six healthy donors. Fold change for: (A) Bcl2, (B) Mcl-1, (C) Bfl-1, (D) Bcl-b, (E) Bcl-w, and (F) Bcl-xl levels. P-values are
shown.
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2.5 Discussion
ABT-737 was rationally designed to bind selectively to the anti-apoptotic
proteins Bcl-2, Bcl-xl, and Bcl-w that are known to be overexpressed in lymphoid
malignancies (Kitada, Andersen et al. 1998; Pepper, Hoy et al. 1998). There is no
available marker that directly predicts the sensitivity to ABT-737 based on antiapoptotic protein expression levels. The inconsistency of reports on the
correlation of the expression of anti-apoptotic proteins with the ABT-737
response might be due to the difficulty in detecting some of them by Western
blotting in primary cells (Del Gaizo Moore, Brown et al. 2007; Mason, Khaw et
al. 2009; Vogler, Butterworth et al. 2009). This may explain the emphasis that has
been placed on individual anti-apoptotic proteins, such as Bcl-2 and Mcl-1, with
no extensive studies available on the contribution of Bfl-1 and Bcl-b to the ABT737 response in primary CLL. Moreover, the primary use of Western blotting in
most of these studies further limited the development of quantitative approaches.

Here, we report that the anti-apoptotic Bcl-2 family mRNAs are expressed at
different basal levels in lymphocytes from healthy donors. Therefore, comparing
the basal expression levels of the anti-apoptotic transcripts in CLL to healthy
donors could be misleading. In contrast, normalizing these mRNAs to β-actin
provided an equal scale for comparison of their expression in untreated primary
CLL and further establishes their contribution to the ABT-737 response. We
found that Mcl-1, Bcl-2, Bfl-1, and Bcl-b transcripts were more abundant than
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those of Bcl-xl and Bcl-w. However, Mcl-1, Bfl-1, and Bcl-2 appear to be the
most critical anti-apoptotic factors that account for ABT-737 sensitivity. Applying
RT-PCR as a highly sensitive and quantitative assay allowed us to establish a
quantitative comparison between the expression levels of Bcl-2 family members.
Bcl-2, Mcl-1, and Bfl-1 expression were higher in cells sensitive to ABT-737,
with Bcl-2 expression being the highest. These findings may explain why the
sensitivity to ABT-737 in primary CLL was correlated with high Mcl-1 levels in
previous reports (Vogler, Butterworth et al. 2009).

In the moderately sensitive CLL group, Mcl-1 and Bfl-1 levels were higher
than those of Bcl-2, whereas in the resistant group Mcl-1 and Bfl-1 expression
were much higher compared to those of Bcl-2. Our findings reveal that individual
or even combined levels of Mcl-1 and Bfl-1 could not predict ABT-737
sensitivity without accounting for their relative ratio to Bcl-2. This likely reflects
the molecular abundance of Mcl-1, Bfl-1, and Mcl-1, as well as the cellular
balance between low and high affinity ABT-737-binding proteins. Importantly,
our model directly addresses the wide range of ABT-737 responses in primary
CLL that were reported previously (Oltersdorf, Elmore et al. 2005; Mason, Khaw
et al. 2009). The anti-apoptotic Bcl-2 family expression index in a panel of
leukemic tumor cell lines was consistent with our CLL data. This model was also
validated in SCLC as another tumor type. Recent data from a phase I study of
navitoclax (ABT-263) has shown that a high Bcl-2 copy number in circulating
tumor cells was associated with the best tumor response in SCLC patients.
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Remarkably, our predictive model showed a higher correlation with ABT-737
response than expression of Bcl-2 alone in these SCLC cell lines based on data
extracted from the ONCOMINE database (Rhodes, Yu et al. 2004). There are
currently 17 clinical trials (http://clinicaltrials.gov/, 06-13-2011) with the Bcl-2family inhibitor navitoclax, the oral derivative of ABT-737, for CLL, other
hematologic malignancies, and solid tumors for which our predictive model could
also become informative.

We also studied the expression of pro-apoptotic BH3-only Bcl-2 members
Noxa, Bim, and Puma. These pro-apoptotic members are most likely to be
sequestered by anti-apoptotic proteins as the primed for cell death model predicts
(Deng, Carlson et al. 2007). This model posits that cells expressing significant
amounts of BH3-only proteins, such as Bim, must sequester them with antiapoptotic proteins to stay alive. The sensitive CLL group had increased levels of
Noxa, Bim, and Puma. However, as some resistant and intermediate groups also
had high Noxa, Bim, and Puma levels, we could not establish a predictive value
for a BH3-only index and ABT-737 response in the CLL samples we have
examined. Nevertheless, it is possible that including their expression in a Bcl-2
family index may help to predict clinical response to other therapeutics or in other
tumor types.
We have applied both a clinically relevant pharmacologic (flavopiridol) as
well as a genetic (shRNA) approach to reduce Mcl-1 and Bfl-1 levels to improve
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the ABT-737 response in the resistant cell lines. shRNA-expressing cells, in
which expression of either Mcl-1 or Bfl-1 was down regulated, were treated with
a higher ABT-737 concentration as compared to flavopiridol in response to which
both Mcl-1 and Bfl-1 levels were decreased. In addition, there was some
compensation by an increase in the levels of alternative apoptosis-resistance
determinants, Mcl-1 in shBfl-1 and Bfl-1 in shMcl-1-expressing cells.
Nevertheless, these data indicate that clinical agents that reduce Mcl-1 and Bfl-1
levels can be used in combination with navitoclax to maximize their efficacy.

Following ABT-737 treatment, we observed induction of Bfl-1, Bcl-b, and
Bcl-w expression and reduction of Bcl-2 and Mcl-1 levels in most CLL samples.
Bfl-1 and Bcl-b are known to have very low binding affinity for ABT-737;
therefore, their increased levels suggests that these proteins may account for
resistance as a result of long-term ABT-737 exposure, as a published report
indicates (Yecies, Carlson et al. 2010). Here we show that Bfl-1 levels can be
upregulated following ABT-737 treatment in primary CLL not only, as previously
reported, as a result of co-culture of primary CLL with fibroblasts that mimics the
lymph node environment (Vogler, Butterworth et al. 2009). As this is the first
report that reveals the elevated Bcl-b levels following ABT-737 treatment, this
finding suggests a potential novel role for Bcl-b in developing ABT-737
resistance in CLL patients.
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In summary, we have applied RT-PCR as a highly sensitive and quantitative
assay to examine Bcl-2 family transcripts in primary CLL to develop a unique
predictive marker for ABT-737 sensitivity. Our model provides highly predictive
power for ABT-737 sensitivity in primary CLL. This approach requires a small
number of primary cells and allows the study of comparative expression of all
relevant genes. It can also identify whether CLL patients are dependent on Mcl1/Bfl-1 or on Bcl-2 as Mcl-1-dependent leukemic cells have been reported to be
more chemo-sensitive than those that are Bcl-2 dependent (Brunelle, Ryan et al.
2009). Establishing this dependency may guide appropriate ABT-737
administration for future development of novel combinations of ABT-737 with
other targeted agents.
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CHAPTER III
BCL-XL EXPRESSION IS A MARKER OF SHORT TIME TO
TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Sayer Al-harbi et al.

3.1 Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the
western world. Whereas some patients may require immediate therapy and
survive only months, others may live indefinitely untreated. The heterogeneous
clinical course of CLL indicates the need for a prognostic marker that can be used
to predict disease progression and allow better management of the disease.
Common prognostic markers, such as p53, ZAP70, and CD38 are useful in CLL,
but they fail to predict clinical outcome in a substantial number of CLL patients
and limited usefulness in guiding therapeutic decisions. The anti-apoptotic Bcl-2
proteins are overexpressed in lymphoid malignancies, including chronic
lymphocytic leukemia. While extensive studies have focused on the role of Bcl-2
or Mcl-1 in CLL, nothing is known about the role of other anti-apoptotic proteins
and their contribution to clinical outcome in CLL patients. Therefore, we used
RT-PCR as a highly quantitative and sensitive assay to assess expression of all
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known anti-apoptotic Bcl-2 family genes to study their contribution to treatment
free survival in CLL. Our finding indicate that only high Bcl-xl expression is
strongly correlate (P=0.002) with short treatment-free survival. Strikingly, Bcl-xl
was able to identify patients with high risk in the ZAP70 negative and CD38
negative groups as well as in patients with normal/unknown p53 showing a very
powerful prognostic value in CLL.

3.2 Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the
Western world (Lee, Dixon et al. 1987). CLL patients have very wide overall
survival; whereas some patients may survive for months, others may live for
many years (Zwiebel and Cheson 1998; Chiorazzi, Rai et al. 2005). This
heterogonous clinical course led to the search for a prognostic marker that can
predict disease progression. The identification of such markers would enable
individualized counseling and better management of the disease. Immunoglobulin
heavy chain variable-region (VH) gene mutation status and zeta-associated
protein 70 (ZAP70) and CD38 have been proposed to be prognostic markers in
CLL (Damle, Wasil et al. 1999; Hamblin, Davis et al. 1999; Orchard, Ibbotson et
al. 2004; Rassenti, Huynh et al. 2004). Despite their clinical value, there are some
technical difficulties involved in these markers such as labor intensive,
standardization and modification following chemotherapy (Shanafelt, Byrd et al.
2006; Van Bockstaele, Verhasselt et al. 2009). In addition, p53 deletion (del 17p)
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is a well-established marker associated with short survival and chemoresistance.
However, p53 deletion accounts only for a small percentage of CLL patients
(Dohner, Stilgenbauer et al. 2000; Bottcher, Ritgen et al. 2012); One study found
the prevalence of p53 mutation in a large CLL cohort to be less than 8% of the
cases (Zenz, Krober et al. 2008; Gonzalez, Martinez et al. 2011). Overall, these
established prognostic markers fail to predict clinical outcome in a considerable
number of CLL patients (Bottcher, Ritgen et al. 2012). Moreover, it is difficult to
combine the results of these variables markers to asses the risk in individual
patients (Shanafelt, Byrd et al. 2006). Thus, additional prognostic markers for
CLL patients are of interest.

Blocked apoptosis is a hallmark of treatment-resistant cancers and thus, may
highlight the potential application of Bcl-2 family members as prognostic markers
(Letai 2008; Hanahan and Weinberg 2011). In fact, several studies have linked
Bcl-2 family expression and response to chemotherapy in different type of
cancers. It has been recently reported that patients with cancers highly primed to
cross the apoptotic threshold exhibited superior clinical responses to
chemotherapy (Ni Chonghaile, Sarosiek et al. 2011). However, in CLL, high Bcl2 and Mcl-1 levels have been reported to mediate resistance to chlorambucil,
fludarabine, and rituximab (Thomas, Pepper et al. 2000; Hussain, Cheney et al.
2007; Pepper, Lin et al. 2008). Another report finds Mcl-1-dependent leukemias
are more sensitive to a wide range of chemotherapeutic agents than Bcl-2
dependent (Brunelle, Ryan et al. 2009). In addition, we have recently shown that
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relative expression of Mcl-1 and Bfl-1 to Bcl-2 predicts ABT-737 response in
hematological cells, including CLL and solid malignancies (Al-Harbi, Hill et al.
2011). Nevertheless, while numerous studies have focused on the role of Bcl-2 or
Mcl-1 in CLL, nothing is known about the role of other anti-apoptotic proteins
and their contribution to clinical outcome in CLL patients. Here, we used RTPCR as a highly quantitative and sensitive assay to assess expression of all antiapoptotic genes, including Bcl-2, Mcl-1, Bcl-xl, Bcl-w, Bfl-1, Bcl-b and proapoptotic Bim, Puma and Noxa to study their contribution to treatment free
survival in 76 CLL patients. Our data indicate that Bcl-xl was the only antiapoptotic member to demonstrate a very strong correlation with treatment-free
survival. Interestingly, Bcl-xl was able to identify patients with high risk in
ZAP70 negative, CD38 negative groups as well as the p53 unmutated/unknown
group, which indicates a superior and independent prognostic value.

3.3 Methods
3.3.1 Purification of primary CLL cells
Peripheral blood samples from 76 patients with CLL were obtained with the
patients’ informed consent according to protocols approved by the Cleveland
Clinic Institutional Review Board according to the Declaration of Helsinki. All
primary CLL cells were freshly processed without freezing. Lymphocytes were
purified by Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation.
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3.3.2 Flow cytometry
It has been previously described in 2.3.3 (Al-Harbi, Hill et al. 2011).
3.3.3 FISH
It has been previously described in 2.3.4

3.3.4 RNA isolation and quantitative RT-PCR
It has been previously described in 2.3.6 (Al-Harbi, Hill et al. 2011).
3.3.5 Statistical analysis
Cox-proportional hazard models were used to identify significant survival
dependencies via slope coefficients differing significantly from zero. To graph
these dependencies, Kaplan-Meier methods were applied with covariates
dichotomized at their medians. P values shown in such plots were obtained using
the log rank test. Two sample t-tests were used to compare Bcl-xl levels between
low and high levels of ZAP70, CD38 and p53. All computations were performed
in R.
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3.4 Result and discussion
Baseline characteristics of the 76 CLL patients studied are summarized in
(Table 3.1). We have used RT-PCR as a quantitative assay to assess expression all
anti-apoptotic Bcl-2 family genes: Bcl-2, Mcl-1, Bcl-xl, Bcl-w, Bcl-b and Bfl-1 as
well as pro-apoptotic members: Bim, Puma and Noxa. We tested the correlation
of expression level of each member with treatment-free survival (Figure 3.1 and
3.2). To test the impact of each member on the treatment-free survival, the
patients were categorized into two subsets, high (above) and low (below) the
median expression value for each Bcl-2 family member. We also examined the
combined expression of all anti-apoptotic members, all pro-apoptotic members,
and the ratio of these, with treatment-free survival. From all these analyses only
Bcl-xl expression emerged as significant and correlate with treatment-free
survival (Figure 3.1A). Interestingly, Bcl-xl expression did not significantly
correlate with Rai stage (Figure 3.3), CD38, ZAP70, and commonly detected
chromosomal abnormalities (Table 3.1), indicating that Bcl-xl expression is
independent of known CLL prognostic markers. We also assessed the correlation
of common CLL prognostic markers: p53, CD38 and ZAP70 with treatment-free
survival. Patients with p53 deletion also show very strong correlation with
treatment-free survival, where ZAP70 and CD38 failed to show any correlation
with treatment free-survival (Figure 3.4).

82

Interestingly, we have noticed that some patients in ZAP70 negative, CD38
negative, normal/unknown p53 categories also experience rapid progression and
aggressive disease (Figure 3.4). This suggests that some patients in these
categories are still at high risk, and the current prognostic markers may be limited
in identifying those patients. Therefore, we wanted to test the ability of Bcl-xl to
identify patients with high risk within ZAP70 negative, CD38 negative, and p53
normal/unknown categories. Surprisingly, Bcl-xl was able to identify patients
with high risk in the ZAP70 negative and CD38 negative groups as well as
patients with normal/unknown p53 showing a very strong prognostic value in
CLL (Figure 3.5).
As Bcl-xl provides a comprehensive and powerful prognostic marker in CLL,
it was not surprising that Bcl-2 and Mcl-1 failed to show significance in
treatment-free survival since other studies report similar findings (Grever, Lucas
et al. 2007; Pepper, Lin et al. 2008). There are conflicting reports on the
significance of ZAP70 and CD38 in predicting the clinical outcome in CLL
(Grever, Lucas et al. 2007). Lack of method standardization following
chemotherapy have been associated with the use of these markers (Shanafelt,
Byrd et al. 2006; Sheikholeslami, Jilani et al. 2006; Van Bockstaele, Verhasselt et
al. 2009). Despite of these shortcomings, ZAP70, and CD38 are often performed
as part of the diagnostic evaluation in CLL patients. An interesting finding of this
study is that Bcl-xl was able to identify high-risk patients within ZAP70-negative
and CD38-negative groups. More importantly, the prevalence of p53 deletion or
mutation has been reported in only a small proportion of CLL patients.
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Remarkably, Bcl-xl was able to mark patients with high risk in p53
undeleted/unknown group, which may indicate Bcl-xl as ideal prognostic marker
in this group.
The role of bcl-xl and survival has not been investigated in CLL; however
recent reports show that Bcl-xl is essential for lymphoma development (Kelly,
Grabow et al. 2011). In support of our findings, the resistance to a group of
compounds that repress Mcl-1 expression was correlated with high mRNA
expression of Bcl-xl, indicating that patients-selection strategy for development of
any Mcl-1 inhibitor in breast and non-small cells lung carcinoma (NSCLC)
tumors should be based on patients with low Bcl-xl expression (Wei, Margolin et
al. 2012). Resistance to 122 standard chemotherapy agents was also correlated
with high Bcl-xl expression in the NCI 60 cell line panel (Amundson, Myers et al.
2000) which suggest its unique role in mediating general chemotherapy
resistance.
In summary, in an extensive study that quantify all anti-apoptotic genes by
using RT-PCR as a simple, highly sensitive, cost effective technique, we propose
Bcl-xl as an independent prognostic marker that can predict high risk in diverse
CLL patients.
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Table 3.1: Baseline characteristic of CLL patients
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Figure 3.1: Kaplan-Meier curves for correlation of treatment-free survival
with anti-apoptotic Bcl-2 expression levels. (A) BCL-XL, (B) BCL-2, (C)
MCL-1, (D) BFL-1, (E) BCL-W, (F) BCL-B.
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Figure 3.2: Kaplan-Meier curves for correlation of treatment-free survival
with pro-apoptotic Bcl-2 expression levels. (A) PUMA, (B) NOXA, (C) BIM.
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Figure 3.3: BCL-XL expression is independent of Rai stage. RNA expression
of BCL-XL, as determined by quantitative RT-PCR in 0, I, II, III, and IV stages.
P-values are indicated for comparison between groups.
.
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Figure 3.4: Kaplan-Meier curves for correlation of treatment-free survival
with CLL prognostic markers. (A) 17p deletion, (B) CD38, (C) ZAP70.
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Figure 3.5: Kaplan-Meier curves for BCL-XL correlation with treatmentfree survival in negative CLL prognostic marker groups. (A) CD38 negative
group, (B) ZAP70 negative group, (C) 17p negative/unknown group.
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CHAPTER IV
MCL-1 STABILITY DEFINES ABT-737 RESISTANCE IN LEUKEMIC BCELLS
Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Cancer Res. 2012 Apr 23.

4.1 Abstract
ABT-737 is a small molecule Bcl-2 homology BH3 domain mimetic that binds
to the Bcl-2 family proteins Bcl-2 and Bcl-xL. Recent clinical trials show that the
drug is highly effective however, the most effective chemotherapeutics acquired
resistance is a serious clinical problem. In order to investigate the potential
mechanism responsible for ABT-737 resistance. We generated ABT-737 resistant
(ABT-R) cell lines from initially sensitive Nalm-6 and Reh after chronic exposure
to ABT-737. Compared with parental cells, cells that have developed acquired
resistance to ABT-737 showed increased expression of Mcl-1. Mcl-1 was not
transcriptionally upregulated as there was no difference in constitutive Mcl-1
mRNA levels in resistant and parental Nalm-6 and Reh cells. Our result indicates
that increased Mcl-1 levels of ABT-R cells were due to its stabilization at the
protein. We also show that increased Mcl-1 levels are associated with Bim in
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ABT-R cells which mediate resistance to ABT-737. These data therefore reveal
novel insights into mechanisms of acquired resistance to ABT-737.

4.2 Introduction
The interplay between Bcl-2 family members is essential for controlling the
mitochondrial cell death pathway and thereby the survival of most cells, including
those of hematopoietic origin. Based on their Bcl-2 homology (BH) domains, the
Bcl-2 proteins have been grouped in three classes: anti-apoptotic, pro-apoptotic,
and those with the BH3 domain-only (Chipuk, Moldoveanu et al. 2010; Elkholi,
Floros et al. 2011). The members of this group regulate mitochondrial outer
membrane permeabilization (MOMP), monitoring release of cytochrome c and
activating downstream effector caspases (Chen, Gong et al. 2000). The imbalance
in expression of these partners has been implicated in development of various
tumor types and resistance to chemotherapeutic regimens (Chipuk, Moldoveanu et
al. 2010). This often results from high level expression of anti-apoptotic members,
such as Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bfl-1 that prevent cell death by
sequestering BH3-only proteins, such as Bim, Puma, and Noxa, and regulate
activation of the pro-apoptotic proteins Bax and Bak. In most of these cases, upregulation and binding of significant amounts of anti-apoptotic proteins to
activator proteins keeps these cells alive (Letai 2008; Al-Harbi, Hill et al. 2011).
ABT-737 is a small molecule inhibitor that is effective against certain Bcl-2
family members (Oltersdorf, Elmore et al. 2005). It has a strong affinity for Bcl-2,
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Bcl-xL, and Bcl-w that are bound to Bim by releasing Bim from anti-apoptotic
Bcl-2 partners, thereby initiating MOMP (Morales, Kurtoglu et al. 2011). The oral
derivative of ABT-737, navitoclax (ABT-263) is currently under investigation in
several clinical trials in lymphoid malignancies, such as chronic lymphocytic
leukemia (CLL), and tumors, such as small cell lung cancer (Wilson, O'Connor et
al. 2010; Gandhi, Camidge et al. 2011; Roberts, Seymour et al. 2012).
Importantly, ABT-737 mediated cell death is Bax/Bak-dependent as Bax/Bak
double knock-out mouse fibroblasts are resistant to this treatment (van Delft, Wei
et al. 2006). However, it is expected that even for the most effective
chemotherapeutics acquired resistance to be a serious clinical problem, hence
investigate the potential mechanism responsible for acquired resistance is of
special interest in cancer therapy (Vogler, Dinsdale et al. 2009; Yecies, Carlson et
al. 2010; Shi, Zhou et al. 2011).
ABT-737 has very weak affinity for Mcl-1 (Lee, Czabotar et al. 2007). Various
studies have shown that sensitivity to ABT-737 is decreased in cells expressing
elevated levels of Mcl-1 (Konopleva, Contractor et al. 2006; Al-Harbi, Hill et al.
2011). Moreover, cells initially sensitive to ABT-737 become resistant by upregulating Mcl-1 levels (Yecies, Carlson et al. 2010). To investigate the probable
mechanisms of resistance to ABT-737, resistant cell lines were generated from
pre-B tumor cells that developed increased levels of Mcl-1 protein. This study
reveals novel insights into regulation and role of Mcl-1 in response to ABT-737
resistance.
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4.3 Materials and Methods
4.3.1 Cell lines and reagents
Human B-cell acute lymphoblastic leukemia (ALL) cell lines Nalm-6 and Reh
were obtained from ATCC (Manassas, VA). These pre-B cells express CD19 and
CD127 surface markers with rearranged immunoglobulin heavy chains. Cells
were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals), L-glutamine, Antibiotic-antimycotic (Invitrogen).
ABT-R cells were cultured in 5% FBS. Cell lines were routinely verified for
growth rates, morphological characteristics, and response to stimuli using
Annexin V/Propidium iodide staining. ABT-737 was provided by Abbott
Laboratories (Abott Park, IL). Actinomycin D, and cycloheximide were from
Sigma-Aldrich.
4.3.2 Generation of ABT-737-resistant cell lines
Nalm-6 and Reh cells were cultured in increasing concentrations of ABT-737
administered intermittently, with the drug being washed off to allow cells to
recover. Gradually, the ABT-737 concentration was increased until cells remained
viable when ABT-737 concentrations double to that of their IC50 value was
administered continuously. Cells were treated with verapamil (Sigma-Aldrich) to
exclude the possibility of acquiring resistance due to increase in expression of
drug efflux pumps (Safa, Glover et al. 1987). The ABT-R cells were routinely
monitored for resistance to ABT-737; they were cultured without drug for 72
hours before performing experiments.
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4.3.3 Flow cytometry
Cell death was measured by phosphatidylserine externalization, by staining
with fluorescein-conjugated Annexin V (BD Biosciences, San Jose, CA) and
propidium iodide, and analyzed on a BD FACS Calibur flow cytometer. The raw
data obtained was analyzed by CellQuest Version 5.2.1 software. The results were
normalized to survival of control cells that have been treated with DMSO.
4.3.4 Immunoblotting and immunoprecipitation
Protein lysates were prepared with 1% NP-40 lysis buffer (20 mM Tris-HCl,
pH 7.5; 150 mM Nacl; 1 mM EDTA; 1% NP-40) containing protease inhibitors
(Roche) and phosphatase inhibitors cocktail 2 and 3 (Sigma). The cells were lysed
for 30-45 min at 40C°. 50-60 μg of protein was resolved on 10%-12% SDSPAGE, transferred to nitrocellulose membrane, and immunoblotting was
performed with primary antibodies. For immunoprecipitation cells were lysed
with CHAPS buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; 2%
CHAPS, Calbiochem) containing protease and phosphates inhibitors for 1 hour.
Protein lysates were incubated with primary antibody overnight at 40 C° followed
by 1 hour incubation of protein A agarose beads (eBioscience, Calbiochem) at
40C°. Immunoprecipitates were washed 3 times with CHAPS and eluted with
loading buffer.
The co-immunoprecipitated proteins were resolved by SDS-PAGE. Primary
antibodies used were for Mcl-1, Bim (BD-Biosciences), NOXA (Enzo Life
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Sciences), Bcl-2, Bcl-xL (Santa Cruz Biotechnology), PUMA (ProSci
Corporation), USP-9X (Abnova), PARP1 (Cell Signaling), and β-actin (Sigma).
4.3.5 RNA Isolation and Real-Time Quantitative Polymerase Chain Reaction
(qRT-PCR)
Total RNA was isolated from parental and ABT-R cells after ABT-737
treatment (500-1000 nM) for 4-24 hours using the Trizol method (Invitrogen); 2
µg of RNA was reverse transcribed using the TaqMan reverse transcription kit
and amplified using the SYBR Green Master Mix (Applied Biosystems,
N8080234 and 4309155) and examined on a 7500 Real-Time PCR system
(Applied Biosystems). RNA isolated using primers for Mcl-1 and normalized for
β-actin as described (Al-Harbi, Hill et al. 2011).
4.3.6 Confocal immunostaining
Cells were fixed with 2.0% paraformaldehyde/PBS for 15 min at room
temperature, washed 3 times for 10 min each, permeabilized with 0.1% Triton X100 in PBS for 5 min, and blocked in 10% fetal bovine serum in PBS for 1 hour.
The coverslips were then immunostained using Mcl-1 antibody diluted in
blocking buffer, followed by fluorescently conjugated secondary antibody. DAPI
and Mito-tracker were added to stain Nucleus and Mitochondria respectfully.
They were then mounted in Vectashield (Vector Laboratories, H-1000). Images
were collected using an HCX Plan Apo 63X/1.4N.A. Oil immersion objective
lens on a Leica TCS-SP2 confocal microscope (Leica Microsystems AG).
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4.3.7 Statistical Analysis
Statistical comparisons between groups were conducted by 2-way ANOVA
using Prism software. Standard deviation was calculated from experiments
performed in triplicates and indicated as error bars. All experiments were repeated
three times independently.
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4.4 Results
4.4.1 Acquired resistance of B-cells to ABT-737 after prolonged exposure
ABT-737 is a BH3-mimetic that binds only to certain Bcl-2 family proteins,
such as Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1. In our previous studies we have
shown that patients with increased Mcl-1 levels do not respond to ABT-737 and
thereby become resistant to this drug (Al-Harbi, Hill et al. 2011). Hence, in order
to investigate the mechanism responsible for resistance, we generated ABT-737resistant (ABT-R) cell lines from initially sensitive pre-B Nalm-6 and Reh cells.
These cell lines were selected for their sensitivity to ABT-737, with IC50 values
of ~1000 and ~500 nm, respectively. The Nalm-6 ABT-R and Reh ABT-R cells
generated could tolerate continuous exposure to ABT-737 at a concentration
double to that of their IC50 value (Fig. 4.1A). In addition, Parental cells were
sensitive to ABT-737 and within 3 hours they were committed to cell death, as
indicated by cleavage of poly-(ADP-ribose) polymerase 1(PARP1) (Fig. 4.1B).
These results indicate that ABT-737 resistant cells are highly resistant to ABT737.
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Figure 4.1. Acquired resistance development in leukemic cells. (A) Parental
and ABT-737 resistant (ABT-R) Nalm-6 and Reh cells were treated with ABT737 for 24 hours. Cell viability is shown as a percentage of Annexin V-FITC/PInegative, relative to control cells treated with DMSO, as determined by flow
cytometric analyses. (B) Parental and ABT-R Nalm-6 cells were treated with
ABT-737 (1000 nM for 1-3 hours) and expression of PARP1, and β-actin was
determined by immunobloting.
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4.4.2 Mcl-1 levels are high in ABT-737 resistant cells
Further examination of Bcl-2 family proteins by immunoblotting in parental
and ABT-R cells indicated increased Mcl-1 levels in ABT-R cells (Fig. 4.2A).
Bfl-1 levels were below our detection limit. We could also observe decreased Bcl2 and increased Bim levels in Reh ABT-R cells, which were comparable to those
found in Nalm-6 ABT-R cells. Puma and NOXA expression was not markedly
altered (Fig. 4.2A). Mcl-1 protein levels increased in parental but not in ABT-R
cells following acute ABT-737 treatment (Fig. 4.2B).
Increased Mcl-1 levels were attributed to increased deubiquitination as a result
of increased levels of the USP9X deubiquitinating enzyme (Schwickart, Huang et
al. 2010), however, USP9X levels (Fig. 4.2B) and its association with Mcl-1 (data
not shown) did not change in ABT-R cells. To validate our immunoblotting data,
we performed immunostaning experiment to asses expression and localization of
Mcl-1 in parental and ABT-737 resistant cells. Our data indicate that Mcl-1
expression is high in ABT-737 resistant cells and predominantly localized in the
mitochondria (Figure 4.3). Similar results were found for Nalm6R (data not
shown). Our results show that ABT-737-resistant cells could block apoptosis and
develop resistance by elevating Mcl-1 levels.
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Figure 4.2. High Mcl-1 level in ABT-R cells. (A) Whole cell lysates were
analyzed by immunoblotting for expression of Bcl-2 family proteins and β-actin
by immunobloting with the indicated primary antibodies. (B) Parental and ABT-R
Nalm-6 cells were treated with ABT-737 (1000 nM for 1-3 hours) and
expressions of Bim, USP 9X, PARP, Mcl-1, and β-actin were determined by
immunobloting. The results are representative of three independent experiments.
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Figure 4.3 Expression and localization of Mcl-1 in parental and Reh ABT737-resistant cells. Confocal co-immunostaining for Reh parental and Reh ABT737-resistant cells stained with Mcl-1 (green), Mitochondria (red), and Nucleus
(blue).
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4.4.3 ABT-737 resistance is associated with increased Mcl-1 protein stability
Previous studies of acquired ABT-737-resistance reported that increased
expression levels of Mcl-1 in ABT-R cells are a result of increased mRNA levels
(Yecies, Carlson et al. 2010). However, there was no difference in constitutive
Mcl-1 mRNA levels in resistant compared to parental Nalm-6 and Reh cells, as
determined by qRT-PCR (Figure. 4.4 A-B). Similar results were found for Bfl-1
(data not shown). Most importantly, there was no change in Mcl-1 mRNA levels
following chronic ABT-737 treatment in Nalm-6 (1000 nM) and Reh (500 nM)
parental and ABT-R cells. These results indicate that Mcl-1 was not
transcriptionally upregulated, however do not preclude the possibility of a
reduced turnover of the Mcl-1 transcript in ABT-737-resistant cells. ABT-R
Nalm-6 and Reh cells examined up to 2 hours following treatment with
actinomycin D, a known transcriptional inhibitor, indicated that the half-life of
Mcl-1 mRNA was not altered (data not shown). In addition, there was no further
change of Mcl-1 proteins levels in ABT-R cells following 18 hours ABT-737
exposure (Figure 4.4C).
Since the Mcl-1 protein has a very short half-life, Mcl-1 protein stability was
further evaluated. Immunoblotting following 30-90 min of cycloheximide
treatment revealed that the half-life of Mcl-1 protein was increased considerably,
to 60-90 min in ABT-R compared to 15-20 min in parental cells (Fig. 4.5A-C).
These results indicate that increased Mcl-1 levels of ABT-R cells were due to its
stabilization at the protein and not at mRNA level.
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Figure 4.4. Increased Mcl-1 levels in ABT-737-resistant cells are not due to
regulation of mRNA expression. (A) Mcl-1 mRNA levels were examined by
quantitative real-time PCR in parental and ABT-R Nalm-6 and Reh cells
following ABT-737 treatment (1000 nM for Nalm-6 ABT-R and 500 nM for Reh
ABT-R) for 4, 8 and 24 hours. (B) Analyses of Mcl-1 mRNA basal levels were
performed in parental and ABT-737-resistant Nalm-6 and Reh cells by
quantitative real-time PCR. (C) ABT-R cells were treated with ABT-737 (1000
nM for Nalm-6 ABT-R and 500 nM for Reh ABT-R) for 18 hours and
immunoblotted with Mcl-1 and β-actin primary antibodies.
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Figure 4.5. Mcl-1 levels are regulated by protein stabilization. (A) Mcl-1
protein stability was determined following 10 µg/ml cycloheximide (CHX)
treatment in Nalm-6 and Nalm-6 ABT-R cells. (B) Nalm-6 and Nalm-6 ABT-R
cells were pretreated with ABT-737 (500 nM) for 3 hours prior to exposure to
CHX to determine Mcl-1 protein stability. (C) Mcl-1 protein half-life was
determined in Reh and Reh ABT-R cells following CHX treatment.
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4.4.4 Increased Mcl-1 levels sequester Bim following its displacement from
Bcl-2 and Bcl-xl complexes in ABT-R cells
It has been reported that increased Mcl-1 levels in ABT-R cells associate with
Bim after its competitive dissociation from Bcl-2/Bcl-xl complexes by ABT-737.
Importantly, displacement of Bim from Bcl-2/Bcl-xl complexes by ABT-737 in
sensitive cells was shown to be a critical event for committing cells to death
(Yecies, Carlson et al. 2010). We investigated the interaction of Bim with Mcl-1,
Bcl-2, and Bcl-xl in parental and ABT-R Nalm-6 cells. There was less association
of Bim with Bcl-2/Bcl-xl in ABT-R compared to parental Nalm-6 cells, which
was in contrast to binding of Bim to Mcl-1 (Figure 4.6A). Indeed, our coimmunoprecipitation analyses indicated that association of Mcl-1 with Bim in
ABT-R cells was more pronounced compared to those in parental cells. These
results were confirmed by reciprocal immunoprecipitation-immunoblot analyses
with Mcl-1 and Bim, respectively (Figure 4.6B). On other hand, there was more
Bim present that was not bound to Mcl-1 in parental cells, instead was found in
the supernatant following immunodepletion of Mcl-1 (Figure 4.6B). Taken
altogether, these data suggest that Bim was dissociated from Bcl-2/Bcl-xl
complexes by competitive displacement by ABT-737. Moreover, this displaced
Bim was bound to Mcl-1 in resistant but not in parental cells, even when ABT737 was absent. Similar observations were made in Reh ABT-R cells (data not
shown).
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Figure 4.6. Increased Mcl-1 levels are associated with Bim in ABT-R cells.
(A) Bim was immunoprecipitated and immunoblot analyses were performed for
Mcl-1, Bcl-2, Bcl-xl, and Bim. (B) Reciprocal immunoprecipitation analysis was
performed for Mcl-1 followed by immunoblotting for Bim to determine Mcl-1
bound and free Bim. Bim was immunoprecipitates from cells treated with ABT737 (1000 nM) for 3 hours and immunoblotted for Mcl-1 and Bim to determine
the proportion of Mcl-1-bound and Mcl-1-free Bim.
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4.5 Discussion
Acquired resistance is a concern for chemotherapeutic treatments used for
leukemia, and other malignancies. Although there have been basic advances in
understanding the mechanisms for this resistance, few efforts have been made to
study the contribution of post-translational regulation of proteins that leads to
such resistance. The focus of our current studies was to understand the
mechanism responsible for acquired ABT-737 resistance in leukemic cells.
Nuclear magnetic resonance (NMR) studies have shown that ABT-737 binds to
Bcl-2, Bcl-xl, and Bcl-w at sub-nM concentrations, but not to Mcl-1. Hence, Mcl1 levels can determine ABT-737 sensitivity (Yecies, Carlson et al. 2010).
Moreover, increased levels of these proteins can be a frequent cause of resistance.
Various drugs, such as flavopiridol, R-roscovitine (Seliciclib), and PHA 767491
that downregulate Mcl-1 at mRNA level are being tested for sensitizing such
tumor cells (Raje, Kumar et al. 2005; Yecies, Carlson et al. 2010).
Recently, sorafenib (BAY43-9006;Nexavar) was shown to induce apoptosis by
downregulation of Mcl-1 at translational rather than post-translational level
(Huber, Oelsner et al. 2011). This study has examined the molecular mechanism
for acute versus chronic response to ABT-737 in leukemic cells. Recent studies
and our previous report indicate that increased levels of Mcl-1 accumulate in
ABT-R cells, with Mcl-1 being bound to Bim significantly more in resistant
compared to parental cells (Yecies, Carlson et al. 2010; Al-Harbi, Hill et al.
2011). As in our leukemic model of ABT-737 resistance, Mcl-1 was not
upregulated at transcriptional level, led us to explore its protein stability. Previous
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studies have shown that post-translational modifications, such as phosphorylation
of Mcl-1 at specific residues are important for it’s binding to BH3-only proteins
and its stability (Kobayashi, Lee et al. 2007; Liao, Zhao et al. 2011). Mcl-1 is a
short-lived protein and it is a target of E3 ubiquitin ligases that mediate its
proteasomal-mediated degradation. Mcl-1 is inaccessible to E3-ubiquitin ligases,
FBW7 and β-Trcp when it is bound to BH3-only proteins, such as Bim, as more
association of Bim with Mcl-1 prevents their access to Mcl-1. As there is
competitive binding between these E3-ubiquitin ligases and BH3-only proteins
because they share the same C-terminal-binding region of Mcl-1 (Hogarty 2010),
most likely this could contribute towards Mcl-1 stability, as more Bim is
associated with Mcl-1 in ABT-R cells. These findings provide insights into the
molecular mechanism of ABT-737 resistance.
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CHAPTER V
FUTURE DIRECTIONS

5.1 Introduction
Apoptosis is often blocked in cancer, which limits the response to conventional
therapy. Resistance of tumor cells to conventional chemotherapy may be caused
by a defect in the apoptosis machinery. It is clear that high levels of anti-apoptotic
proteins have been reported in many human malignancies and generally correlate
with aggressive tumors and chemotherapeutic resistance. However, it is not clear
how to apply the expression of anti-apoptotic Bcl-2 genes in a rational way to
predict the maximum response to current chemotherapy regimens in cancer
patients.
We have developed a marker that can be used to predict responses in leukemia,
including CLL as well as small cell lung carcinomas cells. We have also shown
that combining ABT-737 with agents that target high Mcl-1 levels, such as
flavopiridol, can improve the clinical response in highly ABT-737-resistant cells.
However, data from the flavopiridol clinical trials indicate that the drug is not
quite safe, as there is a substantial risk for tumor lysis syndrome (TLS) in the
treated relapsed CLL patients (Blum, Ruppert et al. 2011). Therefore, we wanted
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to test whether disrupting the proliferative signal that mediates the growth and
survival of CLL cells, along with ABT-737, will lead to increased response rates
in CLL patients.
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5.2 Effect of ABT-737 in combination with CAL-101 on ABT-737-resistant
cells.
CAL-101 is a novel small molecule inhibitor of the delta isoform of
phosphatidylinositol 3-kinase. CAL-101 targets the B-cell receptor that is reported
to promote CLL cell growth and survival, which can block the interaction
between the tumor microenvironment and CLL cells (Herman, Lapalombella et al.
2011; Hoellenriegel, Meadows et al. 2011). The drug is available for oral use, is
well tolerated, and shows impressive clinical effects in phase I trials of refractory
hematologic malignancies including CLL (Lin 2010).
To test whether combining ABT-737 and CAL-101 would improve the clinical
response in CLL, we have treated several primary CLL cells with ABT-737 alone
or in combination with CAL-101. Our data indicate that the combination
treatment shows a synergistic effect more than a single treatment of ABT-737 or
CAL-101. However, we need to collect more ABT-737-resistant cells to have an
adequate number of CLL samples. We also want to investigate how cell death is
mediated by the combination treatment and whether the response is Mcl-1
dependent.

5.3 Anti-apoptotic Bcl-2 profiling as a clinical tool in follow-up patients.
We have used RT-PCR as a highly quantitative assay to study the expression
of the anti-apoptotic Bcl-2 family genes. Unlike other techniques that have been
used in the clinic, our assay can quantify all known anti-apoptotic Bcl-2 or any
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other gene transcripts. It is also highly sensitive, simple, cost-effective and most
importantly, requires only small number of cells. As we have applied this assay to
quantify the expression ratio of Mcl-1, Bfl-1, and Bcl-2 to predict response to
ABT-737, we wanted to take this assay to the next level by assessing the
expression level of anti-apoptotic genes in follow-up CLL patients. We have
generated a large cDNA library of CLL patients, with complete Bcl-2 family
expression profiling. The patients all come to the clinic for follow-up visit.
Therefore, we wanted to compare the anti-apoptotic Bcl-2 profiling between the
first and the second visit. We also wanted to test whether the difference can be
correlated to any clinical outcome such as disease progression or clinical
response. This assay can quantify the modulation in the anti-apoptotic Bcl-2
expression following chemotherapy treatment. Thus, it would allow us to identify
whether CLL cells are Bcl-2 dependent or Mcl-1 dependent, which will provide a
rational way to choose the ideal chemotherapy treatment in order to maximize the
clinical response.

We have collected 17 follow-up cases. The period between the first and second
sample collection ranges between four to 12 months. We compared the expression
levels of Bcl-2, Mcl-1, and Bfl-1 in these samples. We did not detect any
significant difference in the Mcl-1 expression levels between the first and the
second samples. There was a significant increase in Bcl-2 and Bfl-1 expressions
in 7 out of 17 samples (Figure 5.1), and 3 out 7 show some tumor progression
such as lymph node enlargement. These preliminary data were not significant, as
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more CLL samples as well as longer time to monitor are needed in order to have
significant data on those patients. It is also important to expand the anti-apoptotic
profiling to include other anti-apoptotic Bcl-2 family members, such as Bcl-xl, in
the study.
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Figure 5.2 High expressions of Bcl-2 and Bfl-1 in follow-up CLL patients.
Comparison in RNA expression of anti-apoptotic Bcl-2 family members (A) Bcl2, and (B) Bfl-1 as determined by quantitative RT-PCR between 1st and 2nd CLL
samples.
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5.4 To investigate whether high Bcl-xl expression is mediated by somatic
genetic alterations in CLL patients
We have shown that CLL patients with a high Bcl-xl level show significantly
short treatment-free survival. It is well known that cancer progression is driven
mainly through somatic genetic alterations including, gene amplification and
translocations (Beroukhim, Mermel et al. 2010). It is highly valuable to identify
any alteration within a key gene that has a critical role in oncogenesis, such as
Bcl-xl. A recent report shows that Bcl-xl mediates general resistance to many
chemotherapy regimens, however, no data to show whether Bcl-xl upregulation is
due to genetic alterations in CLL patients. The ideal approach to address this issue
is to sequence Bcl-xl gene. However, this would be costly and time consuming.
I hypothesize that high Bcl-xl expression is mediated by gene amplification or
chromosomal translocation that can place the bcl-xl gene under the control of a
highly expressed gene. To test my hypothesis, I will use newly custom-designed
Bcl-xl probes to test whether high Bcl-xl is mediated by gene amplification or
chromosomal translocation in a few CLL patients that are known to have high
Bcl-xl using FISH technique.

The second hypothesize is that Bcl-xl could be upregulated due to deletion of
any microRNA that negatively regulates the Bcl-xl transcript. To test this
hypothesis, I will conduct miroRNA profiling in a small number of our cDNA
samples to identify a miroRNA candidate that can be involved in Bcl-xl
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regulation. These hypotheses do not exclude the possibility that high levels of
Bcl-xl can be due to genetic alterations that constitutively activate its upstream
signaling, such as NF-kb.

5.5 Conclusion
Apoptosis is often impaired in cancer, which can significantly limit the
response to conventional therapy. Since many anti-cancer regimens kill tumor
cells through the mitochondrial pathway, resistance of tumor cells to radiation or
chemotherapy can be due to high levels of anti-apoptotic proteins. However,
applying anti-apoptotic profiling as a diagnostic tool to predict clinical response
is not yet feasible.
In an effort to accomplish this goal, we have shown that our anti-apoptotic
index can identify which CLL patients are most likely to respond to ABT-737,
which cannot be predicted using traditional prognostic markers. We have also
shown that Bcl-xl can be used as a prognostic marker to identify CLL patients that
can be at high risk. This study provides insight into the useful application of antiapoptotic profiling as a clinical tool, and can be a step toward applying
personalized treatment, which may maximize the clinical response in cancer
patients.
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